




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C12N 15/85, C07K 14/65, A61K 48/00, A01K 67/027		A1	(11) International Publication Number: WO 98/24922
			(43) International Publication Date: 11 June 1998 (11.06.98)
(21) International Application Number: PCT/US97/21852		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 1 December 1997 (01.12.97)			
(30) Priority Data: 60/031,539 2 December 1996 (02.12.96) US 08/974,572 19 November 1997 (19.11.97) US			
(71) Applicants: GENEMEDICINE, INC. [US/US]; 8301 New Trails Drive, The Woodlands, TX 77381-4248 (US). BAYLOR COLLEGE OF MEDICINE [US/US]; Texas Medical Center, One Baylor Plaza, Houston, TX 77030-3498 (US).		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
(72) Inventors: COLEMAN, Michael; 50 South Havenridge Drive, The Woodlands, TX 77381 (US). SCHWARTZ, Robert; 4019 Marlowe, Houston, TX 77005 (US). DEMAYO, Francesco, J.; 3626 Merrick, Houston, TX 77025 (US).			
(74) Agents: WARBURG, Richard, J. et al.; Lyon & Lyon LLP, Suite 4700, 633 West Fifth Street, Los Angeles, CA 90071-2066 (US).			

(54) Title: INSULIN-LIKE GROWTH FACTOR I (IGF-I) EXPRESSION SYSTEM AND METHODS OF USE

Restriction Map of the Chicken
Skeletal alpha Actin Gene

(57) Abstract

This invention relates to gene delivery and expression, including gene therapy, by using vectors which encode stable mRNA and methods of using such vectors. In particular, this invention relates to vectors which establish controlled expression of recombinant IGF I

gene that the linker is naturally associated with. The blanking region is to the position for inserting the nucleic acid cassette. The expression vectors of the present invention can also be regulated by a regulatory system and/or constructed with a coating.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon						
CN	China						

AL Albania
 AM Armenia
 AT Austria
 AU Australia
 AZ Azerbaijan
 BA Bosnia and Herzegovina
 BB Barbados
 BE Belgium
 BF Burkina Faso
 BG Bulgaria
 BJ Benin
 BR Brazil
 BY Belarus
 CA Canada
 CF Central African Republic
 CG Congo
 CH Switzerland
 CI Côte d'Ivoire
 CM Cameroon
 CN China

ES Spain
 FI Finland
 FR France
 GA Gabon
 GB United Kingdom
 GE Georgia
 GH Ghana
 GN Guinea
 GR Greece
 HU Hungary
 IE Ireland
 IL Israel
 IS Iceland
 IT Italy
 JP Japan
 KE Kenya
 KG Kyrgyzstan
 KP Democratic People's
 Republic of Korea

LS Lesotho
 LT Lithuania
 LU Luxembourg
 LV Latvia
 MC Monaco
 MD Republic of Moldova
 MG Madagascar
 MK The former Yugoslav
 Republic of Macedonia
 ML Mali
 MN Mongolia
 MR Mauritania
 MW Malawi
 MX Mexico
 NE Niger
 NL Netherlands
 NO Norway
 NZ New Zealand
 PL Poland

SI Slovenia
 SK Slovakia
 SN Senegal
 SZ Swaziland
 TD Chad
 TG Togo
 TJ Tajikistan
 TM Turkmenistan
 TR Turkey
 TT Trinidad and Tobago
 UA Ukraine
 UG Uganda
 US United States of America
 UZ Uzbekistan
 VN Viet Nam
 YU Yugoslavia
 ZW Zimbabwe

DESCRIPTION

INSULIN-LIKE GROWTH FACTOR I (IGF-I) EXPRESSION SYSTEM AND METHODS OF USE

Background of the Invention

This invention relates to vectors which encode stable messenger RNA (mRNA) and methods of using such vectors. In particular, this invention relates to vectors which establish controlled expression of recombinant genes within a tissue, which may be at levels which are useful for gene therapy and other applications. The invention further relates to vectors able to express insulin-like growth factor I (IGF-I).

IGF-I and IGF-II are low molecular weight polypeptide hormones that stimulate growth and differentiation of many cell types, including myoblasts, nerve cells, fibroblasts, chondrocytes, osteoblasts, endothelial cells, and keratinocytes (Daughaday & Rotwein, 1989, *Endocrine Reviews* 10:68-91). Expression of IGF-I is normally induced by growth hormone, and many of the growth-promoting activities of growth hormone are mediated by IGF-I (formerly called somatomedin). IGFs circulate bound to high molecular weight binding proteins that function to increase circulating half-life, inhibit insulin mimetic effects, and modulate biological activities mediated via binding to the type I IGF receptor. IGF-I has a primary role in promoting the differentiation and growth of skeletal muscle. IGFs are key myogenic progression factors which propel myoblast cell division and fusion as well as stimulate late stage muscle growth and hypertrophy. Studies by Florini (Florini & Magri, 1989, *Am. J. Physiol. (Cell Physiol.)* 256:C701-C711) indicate that myogenesis is stimulated by IGFs. During the onset

This coincides with the appearance of muscle-specific gene products.

It was shown (Coleman et al., 1995, *J. Biol. Chem.* 270:12109-12116) that increased biosynthesis and secretion of IGF-I, directed by a myogenic expression vector in C2C12 myoblasts cultures strongly stimulates the expression of myogenic helix-loop-helix factors, MyoD, myogenin, desmin, and skeletal actin mRNAs. Conversely, antisense oligodeoxynucleotides complementary to the 5' sequences of IGF-I or IGF-II mRNA were observed to suppress spontaneous differentiation in myogenic cell lines and the induction of myogenin (Florini et al, 1991, *Molecular Endocrinology* 5:718-724).

Direct evidence that IGF-I plays a role in muscle development was found when the single copy murine IGF-I gene was inactivated by homologous recombination (Powell-Braxton et al., 1993, *Genes Dev.* 7:2609-2617; Liu et al., 1993, *Cell* 75:59-72). By knocking out the IGF-I gene, severe muscle dystrophy and highly reduced myofibrillar organization of the skeletal muscle of these IGF-I mutants resulted. The majority of the mice died at birth due to respiratory failure, which was probably due to incomplete maturation of the diaphragm and intercostal muscles. These observations suggest that IGF-I is a central trophic growth factor required for embryonic muscle development and growth.

Recent studies also demonstrate a role for IGF-I in post-natal muscle growth and hypertrophy. Inclusion of IGF-I in the maintenance media of primary cultures of avian myofibers has been shown to elicit larger fiber diameters, a near doubling in myosin content and increases in protein stability and synthesis compared to untreated cultures (Vandenburg et al., 1991, *Am. J. Physiol.* 260:C475-C484). Administration of growth hormone to

muscles (Englemann et al., 1989, *Mol. Cell. Endocrin.*

63:1-14). When the expression of IGF-I genes was increased through passive mechanical stretch and acute exercise, a corresponding increase in muscle hypertrophy was seen (Elgin et al., 1987, *Proc. Nat. Acad. Sci. USA* 5 84:3254-3258).

Studies also suggest that IGF-I is important in muscle regeneration and repair. The characteristics of regeneration vary with the injury, but invariably involves proliferation of muscle precursor cells (MPC), fusion into 10 myotubes, and reinnervation of the muscle. During muscle regeneration, IGF-I acts as a powerful stimulant of MPC proliferation and differentiation (Grounds, 1991, *Path. Res. Pract.* 187:1-22). Studies indicate that IGF-I is produced in satellite cells and nerves within 24 hours 15 following muscle injury and remains elevated for several weeks. In regenerating rodent muscle, the pattern of IGF-I mRNA in damaged muscle parallels muscle precursor replication from the onset (18-24 hr) to the peak (5 days).

20 Reactive nerve sprouting is a wide-spread phenomenon in the nervous system. Nerve sprouting is believed to be initiated by locally activating factors. Intramuscular nerve sprouting can be detected about 4 days after muscle inactivation by crush denervation. Recent studies of 25 Caroni and Schneider, 1994, *J. Neurosci.* 14:3378-3388, indicate that IGF-I is required for the induction of nerve sprouting. Studies also suggest that overexpression of IG-I *in vivo* may be sufficient to enhance nerve sprouting.

Summary of the Invention

30 The present invention is based in part on the identification of certain nucleic acid sequences which confer advantageous tissue targeting, expression, and secretion properties. Such sequences are utilized to

Expression of these vectors can be tissue specific. These vectors are useful in facilitating enhanced expression in tissues as well as in targeting expression with tissue specificity. These vectors can be used to
5 treat diseases by gene therapy by restricting expression of a gene encoded on the vector to targeted tissues. Vectors containing such sequences are able to provide gene delivery and controlled expression of recombinant genes within tissues; such expression can be at certain levels
10 that are useful for gene therapy and other applications. These vectors can also be used to create transgenic animals for research or livestock improvement.

The ability of the expression vector to provide enhanced product secretion as well as direct expression to
15 specific tissues allows the vector to be used for treating numerous diseases. The above vectors can be used in gene therapy where a vector encoding a therapeutic product is introduced into a tissue so that tissue will express the therapeutic product. For example, the above vectors may
20 be used for treating muscle atrophy associated with neurological, muscular, or systemic disease or aging by causing tissues to express certain trophic factors. The above vectors may be used for treating hemophilias by causing tissues to express certain clotting factors and
25 secrete these factors into the circulation. Furthermore, the vectors above can be used for preventing or treating atherogenesis and atherosclerotic cardiovascular, cerebrovascular, or peripheral-vascular disease by causing tissue to express certain factors involved in lipid
30 metabolism.

In addition, the vectors above can be used for gene replacement of inherited genetic defects or acquired hormone deficiencies such as diabetes, for vaccination in humans or animals to induce immune responses, or for

assessing and exploring novel therapeutic methods, to

assess the effects of chemical and physical carcinogens, and to study the effect of various genes and genetic regulatory elements. Furthermore, transgenic animals can be used to develop commercially important livestock species. The above vectors can also be used to transform cells to produce particular proteins and RNA *in vitro*.

Expression of such vectors having an IGF-I encoding sequence in the body of a vertebrate, e.g., a human, can produce both direct and indirect effects. The IGF-I produces direct effects by the direct action of the IGF-I polypeptide. However, indirect effects may also be produced due to the effect of the IGF-I inducing or turning on the expression of other genes.

In a first aspect, the present invention features a vector for expression of a nucleic acid sequence in tissue by encoding stable mRNA. The vector includes a 5' flanking region which includes necessary sequences for the expression of a nucleic acid cassette, which include a promoter sequence from an actin gene promoter sequence. The vector also includes a 3' flanking region, which includes a 3'UTR and/or a 3' NCR from the 3' region of a growth hormone gene, which enhances secretion of the product expressed from the nucleic acid cassette. Preferably the 3' UTR is from a human growth hormone gene. Alternatively, in related vectors, the 3' sequences may be selected to provide a higher level of retention of the product within a tissue, e.g., within a muscle tissue, rather than enhancing secretion. Such sequences can, for example, be from a skeletal α -actin gene. The vector also includes a linker which connects the 5' flanking region to a nucleic acid. The linker does not contain the coding sequence of a gene that the linker is naturally associated with. That is, the linker is not the normal gene associated with the 5' and 3' regions of the actin gene.

the position for inserting the nucleic acid cassette.

The term "flanking region" as used herein refers to nucleotide sequences on either side of an associated gene. Flanking regions can be either 3' or 5' to a particular gene in question. In general, flanking sequences contain elements necessary for regulation of expression of a particular gene. Such elements include, but are not limited to, sequences necessary for efficient expression, as well as tissue specific expression. Examples of sequences necessary for efficient expression can include specific regulatory sequences or elements adjacent to or within the protein coding regions of DNA. These elements, located adjacent to the gene, are termed *cis*-acting elements. The signals are recognized by other diffusible biomolecules *in trans* to alter the transcriptional activity. These biomolecules are termed *trans*-acting factors. *Trans*-acting factors and *cis*-acting elements have been shown to contribute to the timing and developmental expression pattern of a gene. *Cis*-acting elements are usually thought of as those that regulate transcription and are usually found within promoter regions and within upstream (5') or downstream (3') DNA flanking regions.

Flanking DNA with regulatory elements that regulate expression of genes in tissue may also include modulatory or regulatory sequences which are regulated by specific factors, such as glucocorticoids, androgens, progestins, antiproggestins (PCT US93/04399; PCT US96/04324), vitamin D₃ and its metabolites, vitamin A and its metabolites, retinoic acid, calcium as well as others.

"Modulatory" or "regulatory" sequences as used herein refer to sequences which may be in the 3' or 5' flanking region, where such sequences can enhance activation and/or suppression of the transcription of the associated gene.

"Responsive" or "respond" as used herein refers to the enhancement of activation and/or suppression of a gene.

"Metabolite" as used herein refers to any product from the metabolism of the regulatory factors which regulate gene expression.

In addition to the above, either or both of the 3' or 5' flanking regions can cause tissue specificity. Such tissue specificity provides expression predominantly in a specified cell or tissue.

"Predominantly" as used herein means that the gene associated with the 3' or 5' flanking region is expressed to a higher degree only in the specific tissue as compared to low expression or lack of expression in nonspecific tissue. The 3' or 5' flanking regions singularly or together as used herein can provide expression of the associated gene in other tissues but to a lower degree than expression in tissues or cells where expression is predominate. Expression is preferentially in the specified tissue. Such predominant expression can be compared with the same magnitude of difference as will be found in the natural expression of the gene (i.e. as found in a cell in vivo) in that particular tissue or cell type as compared with other nonspecific tissues or cells. Such differences can be observed by analysis of mRNA levels or expression of natural gene products, recombinant gene products, or reporter genes. Furthermore, northern analysis, X gal immunofluorescence or CAT assays as discussed herein and as known in the art can be used to detect such differences.

The 3' flanking region contains sequences or regions, e.g. 3'UTR and/or 3' NCR, which regulate expression of a nucleic acid sequence with which it is associated. The 3' flanking regions can provide tissue-specific expression to an associated gene. The 3' flanking region also contains a transcriptional termination signal.

The term "3' flanking region" as used herein includes mRNA processing and/or tissue specific expression. That

portion can be readily defined by known procedures. For example, the portions of a 3' flanking region which are responsible for mRNA stability and/or tissue-specific expression can be mapped by mutational analysis or various clones created to define the desired 3' flanking region activity in a selected vector system.

The 3' flanking region can contain a 3'UTR and/or a 3' NCR. The term "3' untranslated region" or "3'UTR" refers to the sequence at the 3' end of structural gene which is transcribed from the DNA but not translated into protein. This 3'UTR region does not contain a poly(A) sequence, but generally contains a site at which a poly(A) sequence is added. Poly (A) sequences are only added after the transcriptional process.

Myogenic-specific 3'UTR sequences can be used to allow for specific stability in muscle cells or other tissues. As described below, myogenic-specific sequences refers to gene sequences normally expressed in muscle cells, e.g., skeletal, heart and smooth muscle cells. Myogenic specific mRNA stability provides an increase in mRNA stability within myogenic cells. The increase in stability provides increased expression. The 3'UTR and 3' NCR sequences singularly or together can provide a higher level of mRNA accumulation through increased mRNA stability. Thus, increased expression and/or stability of mRNA leads to increased levels of protein production.

The term "3' non-coding region" or "3'NCR" is a region which is adjacent to the 3'UTR region of a structural gene. The 3'NCR region generally contains a transcription termination signal. Once transcription occurs and prior to translation, the RNA sequence encoded by the 3'NCR is usually removed so that the poly(A) sequence can be added to the mRNA. The 3'NCR sequences can also be used to allow mRNA stability as described

Either or both of the 3'UTR and 3' NCR sequences can be selected from a group of myogenic-specific genes. Examples of myogenic-specific genes include the skeletal α -actin gene, fast myosin-light chain 1/3 gene, myosin-heavy chain gene, troponin T gene, acetylcholine receptor subunit genes and muscle creatinine kinase gene.

In reference to 3' flanking regions of this invention, the term "growth hormone" refers to a gene product identified as a growth hormone, for example, human growth hormone or bovine growth hormone. Homologous gene sequences are known in the art for a variety of different vertebrate animals. In different embodiments, the vectors can incorporate 3' sequences, including 3' UTR sequences from such growth hormone genes. The 3' sequence can be modified from the sequence naturally found in the animal, for example by the deletion of ALU repeat sequence from human growth hormone 3' UTR. The deletion of ALU repeats or ALU repeat-like sequences can be performed with a variety of 3' sequences; such deletion generally reduces the rate of homologous recombination. A variety of other modifications may also be made without destroying the tissue targeting, stabilizing, and secretion properties of the 3' sequence.

The 5' flanking region is located 5' to the associated gene or nucleic acid sequence to be expressed. Just as with the 3' flanking region, the 5' flanking region can be defined by known procedures. For example, the active portion of the 5' flanking region can be mapped by mutational analysis or various clones of the 5' flanking region created to define the desired activity in a selected vector. The 5' flanking region can include, in addition to the above regulatory sequences or elements, a promoter, a TATA box, and a CAP site, which are in an appropriate relationship sequentially and positionally for

expression" are those elements of the 5' flanking region

which are sequentially and positionally in an appropriate relationship to cause controlled expression of a gene within a nucleic acid cassette. Expression is controlled to certain levels within tissues such that the expressed
5 gene is useful for gene therapy and other applications involving gene delivery. The 5' sequence can contain elements which regulate tissue-specific expression or can include portions of a naturally occurring 5' element responsible for tissue-specific expression.

10 The term "promoter," as used herein refers to a recognition site on a strand of DNA to which RNA polymerase binds. The promoter usually is a DNA fragment of about 100 to about 200 base pairs (in eukaryotic genes) in the 5' flanking DNA upstream of the CAP site or the
15 transcriptional initiation start site. The promoter forms an "initiation complex" with RNA polymerase to initiate and drive transcriptional activity. The complex can be modified by activating sequences termed "enhancers" or inhibitory sequences termed "silencers". The promoter can
20 be one which is naturally (i.e., associated as if it were within a cell *in vivo*) or non-naturally associated with a 5' flanking region.

A variety of promoters can be used. Some examples include thymidine kinase promoter, myogenic-specific
25 promoters including skeletal α -actin gene promoter, fast myosin light chain 1 promoter, myosin heavy chain promoter, troponin T promoter, and muscle creatinine kinase promoter, as well as non-specific promoters including the cytomegalovirus immediate early promoter,
30 Rous Sarcoma virus LTR. These promoters or other promoters used with the present invention can be mutated in order to increase expression of the associated gene. Furthermore a promoter may be used by itself or in combination with elements from other promoters, as well as

"Mutation" as used herein refers to a change in the sequence of genetic material from normal causing a change in the functional characteristics of the gene. This includes gene mutations where only a single base is changed in the natural gene promoter sequences or multiple bases are changed.

The term "intron" as used herein refers to a section of DNA occurring in a transcribed portion of a gene which is included in a precursor RNA but is then excised during processing of the transcribed RNA before translation occurs. Intron sequences are therefore not found in mRNA nor translated into protein. The term "exon" as used herein refers to a portion of a gene that is included in a transcript of a gene and survives processing of the RNA in the cell to become part of a mature mRNA. Exons generally encode three distinct functional regions of the RNA transcript. The first, located at the 5' end which is not translated into protein, termed the 5' untranslated region (5' UTR), signals the beginning of RNA transcription and contains sequences that direct the mRNA to the ribosomes and cause the mRNA to be bound by ribosomes so that protein synthesis can occur. The second contains the information that can be translated into the amino acid sequence of the protein or function as a bioactive RNA molecule. The third, located at the 3' end is not translated into protein, i.e. 3' UTR, contains the signals for termination of translation and for the addition of a polyadenylation tail (poly(A)). In particular, the 3' UTR as defined above can provide mRNA stability. The intron/exon boundary will be that portion in a particular gene where an intron section connects to an exon section. The terms "TATA box" and "CAP site" are used as they are recognized in the art.

The term "linker" as used herein refers to a DNA or RNA fragment prepared by cleavage with some other enzyme. In

particular, the linker provides a recognition site for inserting the nucleic acid cassette which contains a specific nucleic sequence to be expressed. This recognition site may be but is not limited to an endonuclease site in the linker, such as Cla-I, Not-I, XmaI, Bgl-II, Pac-I, XhoI, NheI, Sfi-I. A linker can be designed so that the unique restriction endonuclease site contains a start codon (e.g. AUG) or stop codon (e.g. TAA, TGA, TCA) and these critical codons are reconstituted when a sequence encoding a protein is ligated into the linker. Such linkers commonly include an NcoI or SphI site.

The term "leader" as used herein refers to a DNA sequence at the 5' end of a structural gene which is transcribed and translated along with the gene. The leader usually results in the protein having an n-terminal peptide extension sometimes called a pro-sequence. For proteins destined for either secretion to the extracellular medium or the membrane, this signal sequence directs the protein into endoplasmic reticulum from which it is discharged to the appropriate destination. The leader sequence normally is encoded by the desired nucleic acid, synthetically derived or isolated from a different gene sequence. A variety of leader sequences from different proteins can be used in the vectors of the present invention. Some non-limiting examples include gelsolin, albumin, fibrinogen and other secreted serum proteins.

The term "vector" as used herein refers to a nucleic acid, e.g., DNA derived from a plasmid, cosmid, phasmid or bacteriophage or synthesized by chemical or enzymatic means, into which one or more fragments of nucleic acid may be inserted or cloned which encode for particular genes. The vector can contain one or more unique restriction sites for this purpose and may be capable of

... and may have a linear, circular, or supercoiled configuration and

may be complexed with other vectors or other materials for certain purposes. The components of a vector can include but are not limited to a DNA molecule incorporating: (1) a sequence encoding a therapeutic or desired product; and
5 (2) regulatory elements for transcription, translation, RNA stability and replication.

The vector can be used to provide expression of a nucleic acid sequence in tissue. In the present invention this expression is enhanced by providing stability to an
10 mRNA transcript from the nucleic acid sequence and/or secretion of the therapeutic protein. Expression includes the efficient transcription of an inserted gene or nucleic acid sequence within the vector. Expression products may be proteins including but not limited to pure protein
15 (polypeptide), glycoprotein, lipoprotein, phosphoprotein, or nucleoprotein. Expression products may also be RNA. The nucleic acid sequence is contained in a nucleic acid cassette. Expression of the nucleic acid can be continuous or controlled by endogenous or exogenous
20 stimuli.

The term "control" or "controlled" as used herein relates to the expression of gene products (protein or RNA) at sufficiently high levels such that a therapeutic effect is obtained. Levels that are sufficient for
25 therapeutic effect are lower than the toxic levels. Levels of expression for therapeutic effect within selected tissues corresponds to reproducible kinetics of uptake, elimination from cell, post-translational processing, and levels of gene expression, and, in certain
30 instances, regulated expression in response to certain endogenous or exogenous stimuli (e.g., hormones, drugs).

The term "nucleic acid cassette" as used herein refers to the genetic material of interest which codes for a protein or RNA. The nucleic acid cassette is

transcribed into RNA, and when necessary, translated into

a protein in the transformed tissue or cell. Preferably, the cassette has 3' and 5' ends adapted for ready insertion into a vector, e.g., it has restriction endonuclease sites at each end. In the vectors of this invention, a nucleic acid cassette contains a sequence coding for insulin-like growth factor I (IGF-I), e.g., human IGF-I.

The term "tissue" as used herein refers to a collection of cells specialized to perform a particular function or can include a single cell. The cells may be of the same type or of different types.

The term "gene", e.g., "myogenic genes," as used herein refers to those genes exemplified herein and their equivalence in other animal species or other tissues. Homologous sequences (i.e. sequences having a common evolutionary origin representing members of the same superfamily) or analogous sequences (i.e. sequences having common properties though a distinct evolutionary origin) are also included so long as they provide equivalent properties to those described herein. It is important in this invention that the chosen sequence provide the enhanced levels of expression, expression of the appropriate product, and/or tissue-specific expression as noted herein. Those in the art will recognize that the minimum sequences required for such functions are encompassed by the above definition. These minimum sequences are readily determined by standard techniques exemplified herein.

The term "myogenic" refers to muscle tissue or cells. The muscle tissue or cells can be *in vivo*, *in vitro*, or *in vitro* tissue culture and capable of differentiating into muscle tissue. Myogenic cells include skeletal, heart and smooth muscle cells. Genes are termed "myogenic" or "myogenic-specific" if they are expressed or expressed preferentially in myogenic cells. Vectors are termed

Myogenic activity of vectors can be determined by

transfection of these vectors into myogenic cells in culture, injected into intact muscle tissue, or injected into mammalian oocytes to be stably incorporated into the genome to generate transgenic animals which express the protein or RNA of interest in myogenic cells.

The term "non-myogenic" refers to tissue or cells other than muscle. The tissues or cells can be *in vivo*, *in vitro*, or *in vitro* tissue culture.

In a preferred embodiment, the vector described above may have its 5' flanking region from myogenic genes, in particular the skeletal α -actin gene, e.g., a chicken skeletal α -actin gene. Specifically, this can include a promoter sequence which may be linked with other 5' UTR sequences, which can include an intron. While vectors using the chicken skeletal α -actin promoter and/or other 5' flanking sequences are exemplified herein, the 5' sequences for α -actin genes are highly conserved, therefore, such 5' α -actin sequences can be utilized from other vertebrate species, including, for example, human.

The 3' UTR is from a growth hormone gene, preferably from a human growth hormone gene, and preferably includes a poly(A) signal. This sequence can be linked immediately following the natural translation termination codon for a cDNA sequence coding for the protein or RNA to be expressed. As discussed above, these regions can be further and more precisely defined by routine methodology, e.g., deletion or mutation analysis or their equivalents.

The 5' or 3' sequences may have a sequence identical to the sequence as naturally found, but may also have changed sequences which provide equivalent function to a vector in which such 5' or 3' sequences are incorporated. Such a change, for example, could be a change of ten nucleotides in any of the above regions. In particular, such changes can include the deletion of AAT repeat

Also in a preferred embodiment, the sequence encoding IGF-I is a synthetic IGF-I coding sequence. Such a synthetic sequence has a nucleotide sequence which differs from a natural human IGF-I coding sequence. It is preferred that the sequence utilize optimal codon usage; preferably at least 50%, 70%, or 90% of the codons are optimized. Thus, in preferred embodiments the synthetic DNA sequence has at least 80, 90, 95, or 99% sequence identity to the sequence of SEQ ID NO. 1. In a particular preferred embodiment, the synthetic DNA sequence has at least 95% identity, more preferably at least 99% identity, and most preferably 100% identity to the sequence of SEQ ID NO. 4.

In addition, another embodiment of the above vector may contain a regulatory system for regulating expression of the nucleic acid cassette. The term "regulatory system" as used herein refers to cis-acting or trans-acting sequences incorporated into the above vectors which regulate in some characteristic the expression of the nucleic acid of interest as well as trans-acting gene products which are co-expressed in the cell with the above described vector. Regulatory systems can be used for up-regulation or down regulation of expression from the normal levels of expression or existing levels of expression at the time of regulation. The system contributes to the timing and developmental expression pattern of the nucleic acid.

One construction of a regulatory system includes a chimeric trans-acting regulatory factor incorporating elements of a serum response factor capable of regulating expression of the vector in a cell. The chimeric trans-acting regulatory factor is constructed by replacing the normal DNA binding domain sequence of the serum response factor with a DNA binding domain sequence of a receptor

of activating transcription when an agent or ligand spe-

cific to the receptor binding site binds to the receptor. Thus, regulation can be controlled by controlling the amount of the agent.

The DNA binding domain sequence of a receptor, incorporated into the chimeric trans-activating regulatory factor, can be selected from a variety of receptor groups including but not limited to vitamin, steroid, thyroid, orphan hormone, retinoic acid, thyroxine, or GAL4 receptors. The chimeric trans-activating regulator factor is usually located within the sequence of the promoter. In one preferred embodiment the promoter used in the vector is the α -actin promoter and the receptor is the vitamin D receptor.

"Receptor" as used herein includes natural receptors (i.e., as found in a cell *in vivo*) as well as anything that binds alike and causes compartmentalization changes in a cell.

Another embodiment of the regulatory system includes the construction of a vector with two functional units. One functional unit expresses a receptor. This functional unit contains elements required for expression including a promoter, a nucleic acid sequence coding for the receptor, and a 3' UTR and/or a 3' NCR. The second functional unit expresses a therapeutic protein or RNA and contains, in addition, a response element corresponding to the receptor, a promoter, a nucleic acid cassette, and a 3' UTR and/or a 3' NCR. These functional units can be in the same or separate vectors.

The first functional unit expresses the receptor. It is favorable to use a receptor not found in high levels in the target tissue. The receptor forms an interaction, e.g., ionic, non-ionic, hydrophobic, H-bonding, with the response element on the second functional unit prior to, concurrent with, or after the binding of the agent or

receptor can be from the same nonlimiting group as

disclosed above. Furthermore, the vector can be myogenic specific by using myogenic specific 3' UTR and/or 3' NCR sequences.

In an exemplary preferred embodiment the plasmid can be pIG0552 or a plasmid comprising a nucleotide sequence which is the same as the sequence of pIG0552. This is only an example and is meant to be non-limiting. Thus, sequence changes or variations can be made to one or more of the sequence elements, such as the 5' and 3' flanking regions. The sequences utilized for this exemplary vector have the advantage of providing an IGF-I RNA splice product which produces a polypeptide having a signal sequence of equal length as a form found naturally in muscle and many other tissues.

In this context, the word "same" means that the sequences are functionally equivalent and have a high degree of sequence identity. However, the sequences may have a low level of sequence differences, such as by substitution, deletion, or addition of one or more nucleotides. Such sequences will preferably be less than 10%, more preferably less than 5%, and still more preferably less than 1% of the total sequence.

In particular embodiments, the vectors of the above aspect may alternatively comprise, consist essentially of, or consist of the stated elements or sequences.

By "comprising" it is meant including, but not limited to, whatever follows the word "comprising". Thus, use of the term "comprising" indicates that the listed elements are required or mandatory, but that other elements are optional and may or may not be present. By "consisting of" is meant including, and limited to, whatever follows the phrase "consisting of". Thus, the phrase "consisting of" indicates that the listed elements

are the only elements included and that no other elements may be included. The phrase "consisting of" is limited to other elements that do not interfere with or

contribute to the activity or action specified in the disclosure for the listed elements. Thus, the phrase "consisting essentially of" indicates that the listed elements are required or mandatory, but that other elements are optional and may or may not be present depending upon whether or not they affect the activity or action of the listed elements.

A related aspect of the invention provides a formulation for delivery and expression of an IGF-I gene in a cell, preferably a human IGF-I gene. The formulation includes a vector of the above aspect together with one or more other components which can, for example, act to stabilize the vector or to enhance transfection efficiency, but can also provide other functions. In a preferred embodiment, the formulation includes the vector in a solution having between about 0.5% and 50% polyvinyl pyrrolidone (PVP), preferably about 5% PVP. Preferably, the PVP has a weight average molecular weight of about 50,000 g/mol. Further information is disclosed in PCT US95/17038. However, another example of a formulation includes the vector with a cationic lipid (e.g., as described in U.S. Patent 4,897,355, issued January 30, 1990), and can also include a co-lipid, such as a neutral co-lipid.

In reference to the formulations of this invention, the term "about" indicates that in preferred embodiments, the actual value for a particular parameter is in the range of 50%-200% of the stated value.

Another related aspect of the invention features a transgenic animal, at least some cells of which contain vectors of the first aspect of the present invention. These cells include germ or somatic cells. The transgenic animals can be used as models for studying human diseases, for gene therapy and exploring novel therapeutic methods.

regulatory elements. In addition, transgenic animals can

be used to develop commercially important livestock species.

A fourth related aspect of the present invention features cells transformed with a vector of the present invention for expression of a IGF-I nucleic acid sequence, preferably a hIGF-I nucleic acid sequence.

As used herein, "transformation" is the change in a cell's phenotypic characteristics by the action of a gene expressing a gene product. The gene causing the phenotypic characteristic change has been transfected into the cell.

The term "transfection" as used herein refers to a mechanism of gene transfer which involves the uptake of DNA by a cell or organism. Following entry into the cell, the transforming DNA may recombine with that of the host by physically integrating into the chromosomes of the host cell, may be maintained transiently as an episomal element without being replicated, or may replicate independently as a plasmid. Preferably the transforming DNA does not integrate.

Transfection can be performed by *in vivo* techniques as described below, or by *ex vivo* techniques in which cells are co-transfected with a vector containing a selectable marker. This selectable marker is used to select those cells which have become transformed. It is well known to those skilled in the art the type of selectable markers to be used with transfection/transformation studies. An example of such a marker is a *neo* gene, providing neomycin/kanamycin resistance.

Transfection/transformation can be tissue-specific, i.e., involve the use of myogenic specific vectors which cause expression of the nucleic acid cassette predominantly in the tissue of choice. In particular, tissue specificity

A fifth related aspect of the present invention features methods for transfecting a cell with the vectors of the present invention. These methods comprise the steps of contacting a cell *in situ* with a vector of the present invention for sufficient time to transfect the cell. As discussed above, transfection can be *in vivo* or *ex vivo*.

A sixth related aspect of the invention provides a method for delivery and expression of an IGF-I gene, preferably a hIGF-I gene. The method comprises transfecting a plurality of cells with a vector of the first aspect and incubating the cells under conditions allowing expression of a nucleic acid sequence of the vector, which codes for IGF-I. The "conditions allowing expression" may be any of a variety of conditions, including *in vivo* and *in vitro* conditions. Under such conditions, the cells will produce the gene product from the vector DNA in detectable quantities.

A seventh related aspect of the present invention features a method for treating a disease or condition by transfecting cells with the above-referenced vectors. Such disease or condition may, for example, be localized or systemic. Disease can include but is not limited to muscle atrophy, atherogenesis, atherosclerotic cardiovascular, cerebrovascular, or peripheral vascular disease, diabetes, neuropathy, growth disorders and hemophilia. These vectors contain nucleic acid sequences coding for insulin-like growth factor I.

The muscle atrophy to be treated may be due to any of a variety of different causes. For example, muscle weakness may be primarily due to disuse atrophy which commonly occurs in situations such as joint replacement. Likewise, the muscle weakness and atrophy may be secondary to lower motor neuron injury. Such lower motor neuron

injury may be caused by, for example, peripheral nerve palsy, carpal tunnel syndrome, spinal fracture, or

diabetic neuropathy. The causes may also include genetic causes of muscular atrophy, including, for example, muscular dystrophy. These causes and conditions are only exemplary and are not limiting to the invention.

5 Thus, "localized" disease or condition refers to those in which there is specific nerve or muscle damage or atrophy to a defined and limited area of the body. A specific example is disuse atrophy. A "systemic" disease of condition refers to those which relate to the entire
10 organism, or is widely distributed at a number of locations within the body. Examples include diabetes, growth disorders, neuropathies, and muscular dystrophy.

 The methods of treating disease of the present invention feature methods for establishing expression of
15 IGF-I in tissue by administration of a vector. These methods of use of the above-referenced vectors comprises the steps of administering an effective amount of the vectors to a human, animal or tissue culture.

 The term "administering" or "administration" as used
20 herein refers to the route of introduction of a vector or carrier of DNA into the body. The vectors of the above methods and the methods discussed below may be administered by various routes. In particular a preferred target cell for treatment is the skeletal muscle cell.

25 The term "skeletal muscle" as used herein refers to those cells which comprise the bulk of the body's musculature, i.e., striated muscle.

 Administration can be directly to a target tissue or may involve targeted delivery after systemic administration.
30 The preferred embodiments are by direct injection into muscle or targeted uptake into muscle after intravenous injection.

 The term "delivery" refers to the process by which

 the vector is delivered to the target tissue, such as blood vessels, electroporation, transfection, nebulospray,

iontophoresis, particle bombardment, or transplantation of cells genetically modified ex vivo. Examples of administration include intravenous, intramuscular, aerosol, oral, topical, systemic, ocular, intraperitoneal and/or intrathecal.

The preferred means for administration of vectors described above involves the use of formulations for delivery to the target cell in which the vector is associated with elements such as lipids, proteins, carbohydrates, synthetic organic compounds, or inorganic compounds which enhance the entry of the vector into the nucleus of the target cell where gene expression may occur. A particular example is PVP.

The term "formulation" as used herein refers to non-genetic material combined with the vector in a solution, suspension, or colloid which enhances the delivery of the vector to a tissue, uptake by cells within the tissue, intracellular trafficking through the membrane, endosome or cytoplasm into the nucleus, the stability of the vector in extracellular or intracellular compartments, and/or expression of genetic material by the cell.

In a preferred embodiment of the present invention the vector and formulation comprises a nanoparticle which is administered as a suspension or colloid. The formulation can include lipids, proteins, carbohydrates, synthetic organic compounds, or inorganic compounds. Examples of elements which are included in a formulation are lipids capable of forming liposomes, cationic lipids, hydrophilic polymers, polycations (e.g. protamine, polybrine, spermidine, polylysine), peptide or synthetic ligand recognizing receptors on the surface of the target cells, peptide or synthetic ligand capable of inducing endosomal-lysis, peptide or synthetic ligand capable of targeting material to the nucleus, gold, slow release

such elements. This includes formulation elements

enhancing the delivery, uptake, stability, and/or expression of genetic material into cells. This list is included for illustration only and is not intended to be limiting in any way.

5 Another embodiment of the present invention features the above vectors with coating elements that enhance expression as well as uptake by the cell. The term "coating" as used herein refers to elements, proteins or molecules used to associate with the vector in order to
10 enhance cellular uptake. In particular, coating includes a DNA initiation complex and histones. The coating improves the stability of the vector, its entry into the nucleus, and the efficiency of transcription.

The term "DNA initiation complex" as used herein
15 refers to a complex containing a serum response factor, a transcription initiation factor and a transregulatory factor. The serum response factor is attached to or interacts with the serum response element within the promoter region of the vector. The transcription
20 initiation factor and the transregulatory factor then interact with the serum response factor and the promoter, in particular the TATA box within the promoter, to form a stable DNA complex. The term "histone" as used herein refers to nuclear proteins which associate with and/or
25 bind to DNA, e.g., a vector. The histones can bind specifically or non-specifically to the DNA.

The term "effective amount" as used herein refers to sufficient vector administered to humans, animals or into tissue culture to produce the adequate levels of protein
30 or RNA. One skilled in the art recognizes that the adequate level of protein or RNA will depend on the use of the particular vector. These levels will be different depending on the type of administration and treatment or vaccination.

proteins as defined above) in which the disease being

treated requires the protein to circulate through the body from the general circulation. For example, disorders which might be treated by the present invention include osteoporosis by expression of IGF-I or its binding proteins. The selection of the appropriate protein to treat various diseases will be apparent to one skilled in the art.

In treating disease, the present invention provides a means for achieving: (1) sufficiently high levels of a particular protein to obtain a therapeutic effect; (2) controlled expression of product at levels which are sufficient for therapeutic effect and lower than the toxic levels; (3) controlled expression in certain tissues in order to obtain reproducible pharmacokinetics and levels of gene expression; and (4) delivery using clinically and pharmaceutically acceptable means of administration and formulation rather than transplantation of genetically engineered and selected cells.

In doing so, the present invention provides significant advances over the art. First, promoters from viral genomes and viral vectors which were used to obtain high level expression in tissue, were not able to provide controlled expression. Second, promoters from various tissue-specific genes which were used to obtain controlled expression in transgenic animals and animal models of gene therapy did not have a sufficiently high level of expression to obtain therapeutic effect. In addition, in treating diseases with the present invention, the ability to raise antibodies against protein products does not reflect the ability to achieve controlled expression of proteins within the therapeutic range.

An eighth related aspect of the present invention features a method of gene replacement for inherited

The genetic material which is incorporated into the cells from the above vectors can be any natural or synthetic nucleic acid. For example, the nucleic acid can be: (1) not normally found in the tissue of the cells; (2) normally found in a specific tissue but not expressed at physiological significant levels; (3) normally found in specific tissue and normally expressed at physiological desired levels; (4) any other nucleic acid which can be modified for expression in skeletal muscle cells; and (5) any combination of the above. In addition to the genetic material which is incorporated into tissue, the above reference is also applicable to genetic material which is incorporated into a cell.

Other features and advantages of the invention will be apparent from the following detailed description of the invention in conjunction with the accompanying drawings and from the claims.

Brief Description of the Drawings

Figure 1 is a schematic drawing of the chicken skeletal α -actin gene which includes the location of certain unique restriction sites.

Figure 2 is a schematic representation of a myogenic vector system.

Figure 3 is a schematic diagram of a set of skeletal α -actin/insulin like growth factor-I/skeletal α -actin hybrid genes.

Figure 4 is a schematic representation of the exemplary plasmid pIG0552.

Figure 5 is a schematic drawing of an exemplary expression unit as incorporated in plasmid pIG0552. The functional elements are denoted as: SkA Promoter - 5' promoter region from chicken skeletal α -actin gene

et al., 1995, *J. Biol. Chem.* 270:12109-12116); hIGF-I cDNA

- human IGF-I cDNA (Jansen et al., 1983, *Nature* 306(8):609-611; Powell-Braxton et al., 1993, *Genes Dev.* 7(12B):2609-2617); hGH 3' UTR - 3' untranslated region and poly A addition signal from human growth hormone gene.

5 Figures 6-8 provide a schematic representation of the construction scheme for pIG0552 showing the generalized structures of the starting and intermediate plasmids utilized in that construction process.

10 Figure 9 is a chart showing the codon usage frequencies for highly expressed human genes.

15 Figures 10A and 10B are graphs showing results from a mouse model of nerve crush. Data shown are mean \pm SEM for n=4 to 5 (sham) and n=7 to 8 (crush/control and crush/hIGF-I plasmid) animals/group/time point. Fig. 10A shows the effect of hIGF-I plasmid IM administration on nerve conduction velocity. Fig. 10B shows the effect of hIGF-I plasmid IM administration on electromyograph activity (EMG).

20 Figure 11 provides the sequence encoding hIGF-I as incorporated in pIG0552 (SEQ ID NO. 1).

Figure 12 provides the sequence encoding hIGF-I having optimized codon usage (SEQ ID NO. 4).

Figure 13 provides the amino acid sequence encoded by both SEQ ID NOS. 1 & 4.

25 Figure 14 is an alignment of the hIGF-I coding sequences (SEQ ID NOS. 1 & 4), showing the positions of the nucleotide differences between the two sequences. As indicated, the sequences have approximately 80% identity.

30 Figure 15 schematically shows transgenes encoding hIGF-I used in transgenic mice.

The drawings are not necessarily to scale, and certain features of the invention may be exaggerated in scale and shown in schematic form in the interest of

Detailed Description of the Invention

The vectors and methods of this invention provide for the delivery and expression of IGF-I in mammalian cells, e.g., in human cells. It has been shown that IGF-I plays an important role in normal muscle development, muscle growth and hypertrophy, muscle regeneration and maintenance/regeneration of peripheral nerves.

The following are specific examples of preferred embodiments of the present invention and are not intended to limit the invention. These examples demonstrate how the expression vector systems of the present invention can be used in construction of various cellular or animal models, and how genes can be regulated by sequences within such vectors. The description and utility of such vectors and related vectors is discussed herein and is amplified upon in Schwartz et al., U.S. Patent No. 5,298,422, entitled "Myogenic Vector Systems," and co-pending application Schwartz et al., Application No. 08/472,809, entitled "Expression Vector Systems and Method of Use", which are hereby specifically incorporated by reference herein, including drawings.

Below are provided examples of specific regions of 5' UTR and 3' UTR and/or 3' NCR regions of myogenic genes that can be used to provide certain functionalities to an expression vector, and thus within a transformed cell or animal containing such a vector. Those in the art will recognize that specific portions of these regions can be identified as that containing the functional nucleic acid sequence providing the desirable property, and such regions can be readily defined using routine deletion or mutagenic techniques or their equivalent. Such regions include the promoter, enhancer and cis- and transacting elements of a regulatable system. As noted herein, such

Isolation of Chicken Skeletal α -Actin Gene

The nucleic acid sequence of the skeletal α -actin gene has been characterized in chicken, rat, mouse and human. Fornwald et al, 1982, Nucl. Acids Res. 10:3861-3876; R. Zakut, 1982, Nature 298:857-859; French et al, 1990, Gene (Amst.) 88:173-180; Hu et al, 1986, Mol. Cell. Biol. 6:15-25; Minty et al, 1986, Mol. Cell. Biol. 6:2137-2148. The skeletal α -actin gene is a member of the actin multigene family, which, in vertebrates, is made up of three distinct classes of actin isoforms termed as "cytoplasmic", "smooth muscle", and "striated" on the basis of their cellular distribution and pattern of expression in adult tissues. The striated actins, α -cardiac and α -skeletal, are co-expressed specifically in cardiac myocytes and skeletal myofibers. Expression of the α -cardiac and α -skeletal actin genes is sequentially up-regulated in developing cardiac and skeletal muscle with the skeletal isoform predominating in adult skeletal muscle. (Vandekerckhove & Weber, 1984, J. Mol. Biol. 179:391-413; McHugh et al., 1991, Dev. Biol. 148:442-458; Hayward & Schwartz, 1986, J. Cell Biol. 102:1485-1493.) The chicken skeletal α -actin gene is the most highly expressed gene in adult chicken skeletal muscle comprising approximately 8% of the poly(A) RNA.

Numerous experiments *in vitro* and *in vivo* have established that the regulatory sequences which confer cell type restricted and developmentally regulated expression to the skeletal α -actin gene are primarily concentrated in the immediate 5' promoter region. (Bergsma et al., 1986, Mol. Cell. Biol. 6: 2462-2475; Taylor et al., 1988, Genomics. 3(4): 323-36; Petropoulos et al., 1989, Mol. Cell. Biol. 9:3785-3792; Carson et al., 1995, Am. J. Physiol. 268:C918-24.)

sequences derived from the chicken skeletal α -actin gene

were utilized in construction of the IGF-I expression cassette, though other embodiments can utilize other actin or α -skeletal actin genes.

The primary sequences of the skeletal α -actin genes of the various species were deduced from overlapping cDNA clones. To obtain full genes, the cDNA clones were used to screen genomic DNA. For example, the 25 Kb EcoRI fragment of chicken genomic DNA isolated from a lambda Charon 4A vector, contains the 6.2 Kb skeletal α -actin gene on a single HindIII site of pBR322 is shown in Figure 1. Chang et al., *Mol. Cell. Biol.* 4:2498-2508 (1984). Nuclear transcription runoffs were used to map the transcriptional domain of the skeletal α -actin gene. The chicken skeletal α -actin control sequences have also been characterized (Bergsma et al., 1986, *Mol. Cell. Biol.* 6:2462-2475). DNA probes which encompassed portions of the 5' noncoding, promoter coding, and the contiguous 3' noncoding regions were cloned into M13 vectors which provided sense and antisense probes. Nuclei isolated from fibroblasts, myoblasts and day 19 embryonic muscle cells were used in *in vitro* transcription assays to extend RNA transcripts with radioactive tagged nucleotides. Labeled RNA hybridized to dotted DNA probes showed that transcription terminates approximately 1 kb downstream of the skeletal α -actin gene's poly A addition site. This is within a 800 bp PvuII fragment between +2800 and +3600 nucleotides from the start of transcription.

The 3' UTR and/or 3' NCR can be isolated by restriction endonuclease digestion of the 6.2 Kb actin gene with blunt cutter NaeI, which cuts 30 bp upstream of the translation termination codon TAA. HindIII releases the 3' most portion of the actin gene from the vector pBR322 (Figure 2). The 3'UTR and 3'NCR were used to

cDNA libraries were constructed from total RNA isolated from skeletal muscle. The libraries were screened with probes for skeletal 5' noncoding leader, first intron and up to the

initiation of translation ATG, converted to a NcoI cloning site at +196, was liberated from a M13 double stranded DNA by XbaI and NcoI digestion, Klenow filled in and then linked into the XbaI and blunt SmaI sites of pBluescript II KS. The NcoI site is regenerated by this cloning step.

For certain vectors described in Schwartz et al., Application No. 08/472,809, the 3'UTR and 3'NCR on the 2.3 kb NaeI/HindIII fragment were directionally cloned into a blunt EcoRV site and the adjacent HindIII site of the pBluescript II KS vector cassette. The EcoRV and NaeI sites are destroyed. The restored NcoI site was used to insert cDNA sequences encoding polypeptides. Another cloning vector was constructed by inserting the skeletal α -actin promoter from -411 to -11 adjacent to the 3'UTR and 3'NCR. This expression vector eliminates the first intron and the skeletal actin 5' leader sequence. These two vectors were used in preparing DNA constructs to test the efficacy of the 3'UTR and 3' NCR.

Results obtained using vectors having a skeletal α -actin/IGF-I/skeletal α -actin expression cassette are described below, illustrating the intracellular expression of IGF-I from vector constructs and certain results of such expression.

For the exemplary vectors of the present invention, sequences including the skeletal α -actin promoter and first intron were utilized in conjunction with a IGF-I coding sequence and a hGH 3' UTR/poly(A) signal. Further results are presented below showing effects of IGF-I expression and certain comparative results with skeletal α -actin/IGF-I/skeletal α -actin containing vectors.

Expression Vector Construction Containing Human IGF-I Gene

Constructions containing the skeletal α -actin

structure utilizing skeletal α -actin 5' and 3' sequences

is shown in Figure 2. Certain specific vector constructs with IGF-I are shown in Figure 3.

A first construction (SK202 SVa) was made so that the SV40 poly A addition site and the small t-intron were linked to the 3'UTR of the IGF-I cDNA. The SV40 sequences were added to increase the stability of nuclear IGF-I RNA transcripts. Since the SV40 t-intron might not be entirely suitable in the expression of IGF-I in muscle cells, five other vectors were made.

10 The SK733 NcoI vector contains approximately 411 nucleotides of the skeletal α -actin promoter, the natural cap site, 5' untranslated leader and the first intron. An NcoI site was engineered to create a unique insertion cloning site for the cassette containing the IGF-I cDNA, 15 in which the initiation ATG was also converted to an NcoI site.

The SK733IGF-I construction utilizes its own poly A site. An NaeI/HindIII fragment which incorporated the skeletal α -actin 3' UTR, poly A addition site, and 20 terminating sequences was linked to SK202, SK733 NcoI, IGF-I and to SK733IGF-I which the IGF-I poly A site was deleted and replaced by that of skeletal α -actin. In this way IGF-I RNA transcripts containing the skeletal α -actin 3' UTR are stabilized and accumulate in skeletal muscle 25 cells. In addition, by providing contiguous 3' NCR, IGF-I is buffered against outside genomic sequences and is thus more protected from position effects, when integrated into the genome. In addition, by providing natural terminating sequences, the additional regulatory sequences that mark 30 the transcriptional domain of skeletal α -actin prevent read through transcription, improve tissue specificity, developmental timing and transcriptional activity. Presence of 3'NCR sequence allows for a single copy of the

disclosed in the Schwartz et al. application referenced

above, Application No. 08/472,809. This plasmid has an ampicillin resistance backbone and encodes for IGF-I. The plasmid construct pIG0335 is similar to pIG0100A but it contains a Kanamycin resistance backbone, and is also
5 disclosed in Schwartz et al., Application No. 08/472,809.

The exemplary plasmid vector, pIG0552 was constructed using pIG0100A and pIG0335B and additional constructs (pIG0376A and pVC0289A). A schematic representation of pIG0552 is shown in Fig. 4. The pIG0552B expression
10 plasmid contains a hIGF-I gene expression cassette (Fig. 5) in a plasmid backbone containing a kanamycin-resistance (KanR) gene. The hIGF-I gene expression cassette of pIG0552B contains: 1) a promoter derived from the chicken skeletal α -actin promoter and first intron, 2)
15 the human Insulin-like Growth Factor I (hIGF-I) cDNA, and 3) a 3' UTR/poly(A) signal from the human Growth Hormone (hGH) 3' untranslated region (3' UTR). The plasmid backbone is derived from pBluescript KS+ (Stratagene) with 1) the substitution of a kanamycin-resistance gene (*neo*)
20 and prokaryotic promoter (pNEO, Pharmacia) in place of the ampicillin-resistance gene (*bla*) and 2) the deletion of the fl origin of replication.

Thus, the expression cassette described above differs from the original pIG0100 expression system specifically
25 in the 3' UTR (pIG0100 contains skeletal actin 3' UTR; pIG0552 contains hGH 3' UTR). The hGH 3' UTR was substituted for the skeletal actin 3' UTR because it results in increased delivery of recombinant protein from skeletal muscle to systemic circulation. This result has
30 been observed in both transgenic animal and non-viral gene therapy paradigms (i.e., both integrated and episomal template).

The actual construction of pIG0552B primarily involved the substitution of plasmids pIG0100A, pIG0335B, and

The chicken skeletal α -actin promoter and first intron and hIGF-1 cDNA were obtained from plasmid pIG0100A (R. Schwartz, Baylor College of Medicine). The hGH 3' UTR was obtained from plasmid pIG0376A (R. Schwartz, Baylor College of Medicine). pIG0100A contains the chicken skeletal α -actin promoter and first intron, human hIGF-1 cDNA, and chicken skeletal α -actin 3' untranslated region and 3' flanking sequence in pBluescript KS+. pIG0376A contains the chicken skeletal α -actin promoter and first intron, hGH leader sequence, hIGF-I cDNA, and hGH 3' UTR in pBluescript KS+. As indicated above, the plasmid backbone, pVC0289A, includes the kanamycin-resistance gene, pUC origin of replication, and a multicloning site.

The construction scheme used to produce pIG0552B from pIG0100A, pIG0376A, and pVC0289A required the construction of several intermediate plasmids. The first step in the construction of pIG0552B involved the transfer of the gene expression cassettes from pIG0100A and pIG0376A into pVC0289A, to produce pIG0335B and pIG0336A, respectively. pIG0335B was made by ligating the 3472 base pair (bp) NotI/Acc65I fragment containing the chicken skeletal α -actin promoter and first intron, hIGF-I cDNA, and chicken skeletal α -actin 3' UTR from pIG0100A into the NotI/Acc65I sites of pVC0289A. pIG0336C was made by ligating the 1918 bp NotI/Acc65I fragment containing the chicken skeletal α -actin promoter and first intron, hGH leader sequence, human IGF-I cDNA, and hGH 3' UTR from pIG0376C into the NotI/Acc65I sites of pVC0289A. pIG0526A was constructed by ligating the 1132 bp BamHI fragment containing the chicken skeletal α -actin promoter and first intron and the hIGF-I cDNA from pIG0335B to the 3397 bp BamHI fragment containing the hGH 3' UTR in kanR backbone and a fragment of chicken skeletal α -actin promoter. pIG0526A contains

and the 4057 bp fragment containing the chicken skeletal

α -actin promoter and first intron, hIGF-I cDNA, and hGH 3' UTR in the KanR backbone was religated, creating pIG0533A.

pIG0533A contains a human ALU repeat sequence downstream of the hGH 3' UTR. The human ALU repeat
5 sequence in pIG0533A was deleted to create plasmid pIG0552B. The 395 bp EcoO1091 (blunt-ended with T4 DNA polymerase)/BspEI fragment containing the 3' portion of the hIGF-I cDNA and hGH 3'UTR excluding the ALU repeat
10 ended)/BspI fragment containing the KanR backbone, chicken skeletal α -actin promoter and first intron, and 5' portion of the hIGF-I cDNA from pIG0533A to produce the final plasmid, pIG0552B. The deletion of the ALU repeat greatly reduces the frequency of integration of the vector into a
15 human chromosome. However, both pIG0552 and pIG0533 were found to produce approximately the same amounts of secreted IGF-I.

The actual nucleotide sequence of plasmid pIG0552 was determined by standard methods. The expected nucleotide
20 sequence was assembled electronically using Vector NT version 1.2 (InforMax, Inc., Gaithersburg, MD) from previously determined sub-sequences or retrieved from GenBank as follows: (1) the plasmid backbone which is a derivative of pBluescript (Stratagene) in which the *bla*
25 (*Amp^r*) gene has been replaced with the *neo* (*Kan^r*) gene from transposon *tn5* (nucleotides 1 - 2261); (2) skeletal α -actin promoter (nucleotides 2262 - 2688); (3) skeletal α -actin 5' untranslated region (UTR) and first intron (nucleotides 2689 - 2884); (4) human IGF-I coding sequence
30 and a portion of the hIGF-I 3' UTR (nucleotides 2885 - 3392); (5) pBluescript multiple cloning site (MCS, nucleotides 3393 - 3409), and (6) human growth hormone 3' UTR (nucleotides 3410 - 3509) and 3' flanking sequence

The first base of the plasmid backbone sequence is arbitrarily designated nucleotide #1. Sequence identities between the aligned sequences are indicated by "|". Selected sequence elements are labeled and underlined for reference. Although only one strand for each sequence is depicted, over 47% (nucleotides 1884 - 3599) of pIG0552 was sequenced with multiple reads on both strands. Nucleotides 2268 through 3599 of pIG0552 were identical to the expected sequence. This region of the plasmid includes virtually all of the skeletal α -actin promoter and 5' UTR, the entire hIGF-I coding sequence (bolded), the hGH 3' UTR and flanking sequence. This confirms that this plasmid encodes a protein whose primary amino acid sequence matches that of the native human IGF-I protein.

A total of 8 nucleotide differences (indicated by "**") in other regions of the plasmid were observed between the actual and expected sequences. There is a single nucleotide deletion at position 21 in the expected sequence. This position is one base downstream from a Kpn I restriction site that is the last site in what remains of the pBluescript MCS. There is a single nucleotide difference at position 915 in the expected sequence. This position is in a non-critical region of the bacterial origin of replication. Finally, there are 6 nucleotide differences between positions 2262 and 2268 in the expected sequence. These positions are located at the cloning junction between the pBluescript MCS and the 5' end of the skeletal α -actin promoter sequence. The differences in this non-critical region are most likely the result of cloning artifacts. There is no evidence that any of the observed differences affect the relevant biological properties of pIG0552.

Table I

Plasmid pIG0552 Sequence

Upper Sequence: expected sequence for pIG0552
(nucleotides 1 - 3600) (SEQ ID NO. 2)

5 Lower Sequence: actual sequence for pIG0552
(nucleotides 1 - 3599) (SEQ ID NO. 3)

Xho I Apa I Kpn I *

1 TCGAGGGGGGGCCCGTACCCAGCTTTTGTTCCTTTAGTGAGGGTTAAT
10 TCGAGGGGGGGCCCGTACC-AGCTTTTGTTCCTTTAGTGAGGGTTAAT

51 TTCGAGCTTGGCGTAATCATGGTCATAGCTGTTTCTGTGTGAAATGTT
50 TTCGAGCTTGGCGTAATCATGGTCATAGCTGTTTCTGTGTGAAATGTT

15 101 ATCCGCTCACAATTCACACAACATACGAGCCGGAAGCATAAAGTGATAA
100 ATCCGCTCACAATTCACACAACATACGAGCCGGAAGCATAAAGTGATAA

20 151 GCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTC
150 GCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTC

25 201 ACTGCCCCGCTTTCCAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAA
200 ACTGCCCCGCTTTCCAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAA

30 251 TCGGCCAACGCGCGGGGAGAGGCGGTTTTCGTATTGGGCGCTCTTCCGCT
250 TCGGCCAACGCGCGGGGAGAGGCGGTTTTCGTATTGGGCGCTCTTCCGCT

35 301 TCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTTCGGCTGCGGCGAGCGGT
300 TCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTTCGGCTGCGGCGAGCGGT

40 351 ATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATA
350 ATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATA

45 401 ACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGT
400 ACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGT

50 451 AAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCTGACGA
450 AAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCTGACGA

55 501 GCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGAC
500 GCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGAC

601 TATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCT
550 TATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCT
601 GTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGG

650 AAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCCGGTGT

5
10
15
20
25
30
35
40
45
50
55
60

701 AGGTCGTTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCGTTTCAGCCC
700 AGGTCGTTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCGTTTCAGCCC
751 GACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAG
750 GACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAG
801 ACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAG
800 ACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAG
851 CGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTAC
850 CGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTAC
901 GGCTACACTAGAAAGACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGT
900 GGCTACACTAGAAAGACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGT
951 TACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCG
950 TACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGC AAACAAACCACCG
1001 CTGGTAGCGGTGGTTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAA
1000 CTGGTAGCGGTGGTTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAA
1051 AAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCA
1050 AAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCA
1101 GAAGAACTCGTCAAGAAGGCGATAGAAGGCGATGCGCTGCGAATCGGGAG
1100 GAAGAACTCGTCAAGAAGGCGATAGAAGGCGATGCGCTGCGAATCGGGAG
1151 CGGCGATACCGTAAAGCACGAGGAAGCGGTACAGCCATTGCGCGCCAAGC
1150 CGGCGATACCGTAAAGCACGAGGAAGCGGTACAGCCATTGCGCGCCAAGC
1201 TCTTCAGCAATATCACGGGTAGCCAACGCTATGTCCTGATAGCGGTCCGC
1200 TCTTCAGCAATATCACGGGTAGCCAACGCTATGTCCTGATAGCGGTCCGC
1251 CACACCCAGCCGGCCACAGTCGATGAATCCAGAAAAGCGGCCATTTTCCA
1250 CACACCCAGCCGGCCACAGTCGATGAATCCAGAAAAGCGGCCATTTTCCA
1301 CCATGATATTTCGGCAAGCAGGCATCGCCATGGGTACGACGAGATCCTCG
1300 CCATGATATTTCGGCAAGCAGGCATCGCCATGGGTACGACGAGATCCTCG
1351 CCGTCGGGCATGCGCGCCTTGAGCCTGGCGAACAGTTTCGGCTGGCGCGAG
1350 CCGTCGGGCATGCGCGCCTTGAGCCTGGCGAACAGTTTCGGCTGGCGCGAG
1401 CCCCTGATGCTCTTCGTCCAGATCATCCTGATCGACAAGACCGGCTTCCA
1400 CCCCTGATGCTCTTCGTCCAGATCATCCTGATCGACAAGACCGGCTTCCA

$$(\mathcal{M}_1 \otimes \mathcal{M}_2) \otimes \mathcal{M}_3 = \mathcal{M}_1 \otimes (\mathcal{M}_2 \otimes \mathcal{M}_3) \quad \text{and} \quad (\mathcal{M}_1 \otimes \mathcal{M}_2) \otimes \mathcal{M}_3 = \mathcal{M}_1 \otimes (\mathcal{M}_2 \otimes \mathcal{M}_3).$$

1501 CAGGTAGCCGGATCAAGCGTATGCAGCCGCCCATTCATCAGCCATGAT

1500 |||||CAGGTAGCCGGATCAAGCGTATGCAGCCGCCGATTGCATCAGCCATGAT
5 1551 |||||GGATACTTTCTCGGCAGGAGCAAGGTGAGATGACAGGAGATCCTGCCCCG
1550 |||||GGATACTTTCTCGGCAGGAGCAAGGTGAGATGACAGGAGATCCTGCCCCG
1601 |||||GCAC TTCGCCCCAATAGCAGCCAGTCCCTTCCCGCTTCAGTGACAACGTCG
10 1600 |||||GCAC TTCGCCCCAATAGCAGCCAGTCCCTTCCCGCTTCAGTGACAACGTCG
1651 |||||AGCACAGCTGCGCAAGGAACGCCCGTCGTGGCCAGCCACGATAGCCGCGC
1650 |||||AGCACAGCTGCGCAAGGAACGCCCGTCGTGGCCAGCCACGATAGCCGCGC
15 1701 |||||TGCCTCGTCTGCAGTTCATTTCAGGGCACCGGACAGGTCGGTCTTGACAA
1700 |||||TGCCTCGTCTGCAGTTCATTTCAGGGCACCGGACAGGTCGGTCTTGACAA
20 1751 |||||AAAGAACCGGGCGCCCCGCGCTGACAGCCGGAACACGGCGGCATCAGAG
1750 |||||AAAGAACCGGGCGCCCCGCGCTGACAGCCGGAACACGGCGGCATCAGAG
25 1801 |||||CAGCCGATTGTCTGTTGTGCCAGTCATAGCCGAATAGCCTCTCCACCCA
1800 |||||CAGCCGATTGTCTGTTGTGCCAGTCATAGCCGAATAGCCTCTCCACCCA
1851 |||||AGCGGCCGGAAGAACTGCGTGCAATCCATCTTGTTCAATCATGCGAAACG
1850 |||||AGCGGCCGGAAGAACTGCGTGCAATCCATCTTGTTCAATCATGCGAAACG
30 1901 |||||ATCCTCATCTGTCTCTTGATCAGATCTTGATCCCCTGCGCCATCAGATC
1900 |||||ATCCTCATCTGTCTCTTGATCAGATCTTGATCCCCTGCGCCATCAGATC
35 1951 |||||CTTGGCGGCAAGAAAGCCATCCAGTTTACTTTGCAGGGCTTCCCAACCTT
1950 |||||CTTGGCGGCAAGAAAGCCATCCAGTTTACTTTGCAGGGCTTCCCAACCTT
2001 |||||ACCAGAGGGCGCCCCAGCTGGCAATCCGGTTTCGCTTGCTGTCCATAAAA
40 2000 |||||ACCAGAGGGCGCCCCAGCTGGCAATCCGGTTTCGCTTGCTGTCCATAAAA
2051 |||||CCGCCCAGTCTAGCAACTGTTGGGAAGGGCGATCGGTGCGGGCCTCTTCG
2050 |||||CCGCCCAGTCTAGCAACTGTTGGGAAGGGCGATCGGTGCGGGCCTCTTCG
45 2101 |||||CTATTACGCCAGCTGGCGAAAGGGGGATGTGCTGCAAGGCGATTAAAGTTG
2100 |||||CTATTACGCCAGCTGGCGAAAGGGGGATGTGCTGCAAGGCGATTAAAGTTG
50 2151 |||||GGTAACGCCAGGGTTTTCCAGTCACGACGTTGTAACGACGGCCAGTG
2150 |||||GGTAACGCCAGGGTTTTCCAGTCACGACGTTGTAACGACGGCCAGTG
55 2201 |||||AATTGTAATACGACTCACTATAGGGCGAATTGGAGCTCCACCGCGGTGGC
2200 |||||AATTGTAATACGACTCACTATAGGGCGAATTGGAGCTCCACCGCGGTGGC

Sac I Sac II

40

SK promoter ->
Not I *****
2251 GGCCGCTCTAGCTAGAGTCTGCCTGCCCCCTGCCTGGCACAGCCCGTACC
5 2250 GGCCGCTCTAGAGCTTGGCTGCCTGCCCCCTGCCTGGCACAGCCCGTACC
Xba I

2301 TGGCCGCACGCTCCCTCACAGGTGAAGCTCGAAAACCTCCGTCCCCGTAAG
2300 TGGCCGCACGCTCCCTCACAGGTGAAGCTCGAAAACCTCCGTCCCCGTAAG

10 2351 GAGCCCCGCTGCCCCCGAGGCCTCCTCCCTCACGCCTCGCTGCGTCCC
2350 GAGCCCCGCTGCCCCCGAGGCCTCCTCCCTCACGCCTCGCTGCGTCCC

15 2401 GGCTCCCGCACGGCCCTGGGAGAGGCCCCACCGCTTCGTCTTAACGGG
2400 GGCTCCCGCACGGCCCTGGGAGAGGCCCCACCGCTTCGTCTTAACGGG

20 2451 CCCGGCGGTGCCGGGGGATTATTTTCGGCCCCGGCCCCGGGGGGGCCCGGC
2450 CCCGGCGGTGCCGGGGGATTATTTTCGGCCCCGGCCCCGGGGGGGCCCGGC

25 2501 AGACGCTCCTTATACGGCCCGGCCTCGCTCACCTGGGCCGCGGCCAGGAG
2500 AGACGCTCCTTATACGGCCCGGCCTCGCTCACCTGGGCCGCGGCCAGGAG

30 2551 CGCCTTCTTTGGGCAGCGCCGGGCCGGGGCCGCGCCGGGCCCGACACCCA
2550 CGCCTTCTTTGGGCAGCGCCGGGCCGGGGCCGCGCCGGGCCCGACACCCA

35 2601 AATATGGCGACGGCCGGGCCCGCATTCCTGGGGGCCGGGCCGGTGCTCCCG
2600 AATATGGCGACGGCCGGGCCCGCATTCCTGGGGGCCGGGCCGGTGCTCCCG

"TATA" +1 (5' UTR)
2651 CCCGCCCTCGATAAAAGGCTCCGGGGCCGGCGGGCGGCCACGAGCTACCCG
2650 CCCGCCCTCGATAAAAGGCTCCGGGGCCGGCGGGCGGCCACGAGCTACCCG

40 2701 GAGGAGCGGGAGGCGTCTCTGCCAGCGGCCCGACGCGCAGTCAGCACAGG
2700 GAGGAGCGGGAGGCGTCTCTGCCAGCGGCCCGACGCGCAGTCAGCACAGG

45 2751 TAGGTGGGCACCGCGCCGTGCCGTGCCGTGCCGTGCCGTGCCGTGCCGT
2750 TAGGTGGGCACCGCGCCGTGCCGTGCCGTGCCGTGCCGTGCCGTGCCGT

50 2801 TCCGGGGGCCGTGCTGTGGGCCCTCCGTGGGCCCGCCCGTCACCCCTGAGC
2800 TCCGGGGGCCGTGCTGTGGGCCCTCCGTGGGCCCGCCCGTCACCCCTGAGC

Met (IGF-I CDS ->)
2851 CTCACGGCCCCGTGCCCCGAGACAGCCAGCACCATGGGAAAAATCAGCA
2850 CTCACGGCCCCGTGCCCCGAGACAGCCAGCACCATGGGAAAAATCAGCA

2901 GTCTTCCAACCCAATTATTTAAGTGCTGCTTTTGTGATTTCTTGAAGGTG
AAGATGCACACCATGTCTCTCTGGCATCTCTTCTACCTGGCGCTGTGCC

60

41

As noted above, evaluation of the exact sequence of
50 pIG0552 demonstrated that a small number of sequence
changes had occurred as compared to the resulting sequence
predicted based on the sequences of the sequence com-
ponents utilized. It was found that these changes did not

sequences while utilizing the same major sequence elements. Thus, the sequence disclosed is only exemplary.

Instead of the natural sequence coding for IGF-I, it is advantageous to utilize synthetic sequences which encode IGF-I. Such synthetic sequences have alternate codon usage from the natural sequence, and thus have dramatically different nucleotide sequences from the natural sequence. In particular, synthetic sequences can be used which have codon usage at least partially optimized for expression in a human. The natural sequences do not have such optimal codon usage. Preferably, substantially all the codons are optimized.

Optimal codon usage in humans is indicated by codon usage frequencies for highly expressed human genes, as shown in Fig. 9. The codon usage chart is from the program "Human_High.cod" from the Wisconsin Sequence Analysis Package, Version 8.1, Genetics Computer Group, Madison, WI. The codons which are most frequently used in highly expressed human genes are presumptively the optimal codons for expression in human host cells, and thus form the basis for constructing a synthetic coding sequence.

However, rather than a sequence having fully optimized codon usage, it may be desirable to utilize an IGF-I encoding sequence which has optimized codon usage except in areas where the same amino acid is too close together or abundant to make uniform codon usage optimal.

In addition, other synthetic sequences can be used which have substantial portions of the codon usage optimized, for example, with at least 50%, 70%, 80% or 90% optimized codons. Other particular synthetic sequences for IGF-I can be selected by reference to the codon usage chart in Fig. 9. A sequence is selected by choosing a codon for each of the amino acids of the polypeptide

can be synthesized, and then ligated in the appropriate

relationships to construct the full-length coding sequences.

A particular preferred synthetic IGF-I coding sequence is provided in SEQ ID NO. 4.

5 Preparation and Purification of IGF-I Plasmid

A. Preparation of the master cell bank

Competant cells were transfected with the IGF-I plasmid pIG0552 described above. The cells utilized for transformation were MAX Efficiency DH5 α ™ Competent Cells
10 (GIBCO BRL/Life Technologies). The Certificate of Analysis supplied with the cells shows that they exhibit a Lac⁻ phenotype (conferred by *lac* operon deletion), are inhibited by nitrofurantoin (demonstrates *recA1* genotype), and are sensitive to antibiotics commonly used for plasmid
15 stability (ampicillin, kanamycin and tetracycline). The published genotype of *E. coli* DH5 α is F ϕ 80dlacZ Δ M15 Δ (*lacZYA-argF*)U169 *endA1 recA1 hsdR17(r_K⁻m_K⁺) deoR thi-1 supE44 λ gyRA96 relA1.*

Prior to the creation of the master cell bank (MCB),
20 two lots of pIG0552 DNA were produced (pIG0552B.16S and pIG0552B.100). Due to the low plasmid yields and long fermentation time, clone selection was included in the development of the MCB.

To begin clone selection, three colonies were picked
25 from a fresh transformation plate, and designated clones X, Y, and Z. These colonies were simultaneously streaked onto LB-Kan agar plates and inoculated into 50 ml LB-Kan liquid medium. As a control, 20 μ l of pIG0552B was also inoculated into 50 mL LB-Kan; this was designated clone B.
30 The agar plates were incubated overnight at 37°C, wrapped with parafilm and stored at 4°C. The liquid cultures were shaken for 17 hours at 37°C, 250 rpm and then placed in an

6.2 for clones B, X, Y, and Z, respectively. Ethanol

precipitations were performed on each of the undiluted cell lysates.

Clone Z showed improved yields; therefore, five isolated colonies from the pIG0552Z agar plate were picked and inoculated into 500 mL of LB-Kan liquid medium in a baffled Fernbach flask with a foam and cheesecloth stopper. The culture was incubated with shaking for 16 hours, 37°C, 300 rpm and then placed in an ice water bath for cooling. The optical density of the culture was 3.4. Sterile 50% glycerol was cooled on ice, and 120 mL was added to the culture. The culture remained on ice with stirring while approximately 1 mL was dispensed into pre-labeled cryovials. Vials were transferred to the -20°C freezer. The next day, the vials were transferred to -80°C and then to liquid nitrogen for long term storage the following week.

To test the yield of the MCB, one vial was thawed, and 50 μ L was used to inoculate 50 mL of LB-Kan liquid medium. After growth for 16 hours at 37°C, 250 rpm, the culture was analyzed for plasmid yield. The specific yield (mg/g DCW) was 5.2, which is within the expected limits for cultures started from a vial rather than an agar plate.

B. Bulk Preparation

Bulk hIGF-I plasmid is produced using batch fermentation with *Escherichia coli* (*E. coli*, DH5- α) as the host organism. The fermentation and subsequent recovery process steps are described below. For the description below, the process is described taking the following as a basis: 1 liter broth, density (A_{600nm}) of 83, 39.9 g/L dry cell weight (DCW), and 5 mg/g DCW specific yield of crude plasmid, measured at prepurification. These are approximations; actual quantities will vary depending on

1. Solutions used in the process.

Buffers, Media and Solutions Notes:

1) All quantities without ranges are nominal only.

5 2) Quantities with ranges are limited to the range specified.

3) Many buffers containing Tris-HCl are prepared with Tris base, using HCl for pH adjustment.

10 Kanamycin Sulfate - 20 mg/mL Kanamycin sulfate dissolved in WFI, then 0.2 micron filtered and stored in a -20°C freezer.

Primary Seed media (LB) - Tryptone 10 g/L, yeast extract 5 g/L, sodium chloride 10 g/L, water.

15 Secondary Seed Medium - Soytone 15 g/L, yeast extract 15 g/L, sodium chloride 10 g/L, water.

20 Fermentation media (two parts) - (1) Sterilized portion (90%): glycerol 50 ml/liter, yeast extract 50 g/L, $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$ 4-6 g/L, $(\text{NH}_4)_2\text{SO}_4$ 6 g/L; (2) Filtered portion (10%): thiamine hydrochloride 0.15 g/L, vitamin solution (see below) 1000x 3mL/L, K_2HPO_4 6 g/liter, KH_2PO_4 3-5g/L, trace metals solution (see below) 1000x 1-2 mL/L, 0.4 mL/L antifoam and 0025 - 0.5 mg/Kanamycin. All concentrations indicated based on the total volume.

25 Trace metals solution 1000x - $\text{FeCl}_3 \cdot 6\text{H}_2\text{O}$ 100 g/L, in sterile wash for irrigation.

Vitamin solution 1000x - Riboflavin 0.42 g/L, pantothenic acid 5.40 g/L, niacin 6.1 g/L, pyridoxine 1.4 g/L, biotin 0.06 g/L, folic acid 0.04 g/L, sterile water for irrigation, wrap in aluminum foil and store at 2-8°C.

30 Sodium hydroxide - 4-5 M NaOH in deionized water, for adjustment of the fermentation pH.

Phosphoric acid - 20% v/v concentrated phosphoric acid in deionized water, for adjustment of the

Lysis buffer - 200 mM NaOH, 1% sodium dodecyl sulfate (SDS)

Neutralization buffer - A ratio of 35:13:8.75 of 3 M KOAc (pH 5.5), 5 M NaCl, and 7.5 M NH₄OAc.

5 RNase (100x) stock solution - 5 mg/mL RNase A, 10mM Tris-HCl, 15mM NaCl.

Water for irrigation - WFI in bags, purchased from a qualified vendor

10 Q Conditioning buffer - 2 M NaCl, 20 mM Tris-HCl, pH 8.0 prepared with WFI

Q Equilibration buffer - 0.625 M NaCl, 10 mM Tris-HCl, 1mM EDTA, pH 8.0 prepared with WFI

Q Wash buffer - Same as Q equilibration

15 Q Elution buffer- 0.75 M NaCl, 10 mM Tris-HCl, 1mM EDTA, pH 8.0

Q Regeneration solutions (1, 2, and 3) - (1) Same as Q and DEAE conditioning buffer, (2) 1 M NaOH, and(3) 1 M Acetic acid

20 Alkaline hydrolysis solution - 0.1 N NaOH prepared with WFI

Alkaline hydrolysis neutralization solution - 0.1 N HCl prepared with WFI

DEAE Conditioning buffer - same as Q conditioning buffer

25 DEAE Equilibration buffer - 0.33 M NaCl, 20 mM Tris-HCl, pH 7.5 prepared with WFI to a conductivity of 33 1 mS/cm

DEAE Wash buffer - Same as DEAE equilibration

30 DEAE Elution buffer - 0.4 mM NaCl, 20 mM Tris-HCl, pH 7.5, conductivity 39± 1 mS/cm

DEAE Regeneration solutions (1, 2, and 3) - (1) Same as Q and DEAE conditioning buffer, (2) 0.1 M NaOH, and(3) 0.1 M HCl

prepared with WFI

HIC Wash solution - same as HIC equilibration solution

HIC Regeneration solutions (1, 2, and 3) - (1) WFI, (2) 70% (v/v) ethanol, (3) 0.1 N NaOH prepared with WFI

5 Note: WFI is used twice (see flow diagram)

UF/DF diafiltration solutions (1-2) - (1) 1M NaCl prepared with WFI, (2) WFI

Final product dilution - WFI

2. Fermentation Process and Isolation

10 Media Preparation. Media for the seed step is prepared in pre-sterilized Pyrex containers in approximately 2 liter quantities and steam sterilized. The antibiotic is then added after filtering with a presterilized 0.2 micron filter. This sterile seed media
15 is stored at 4°C until needed. Fermentation media is prepared immediately before use. The basal media is sterilized *in situ* and 0.2 micron filter-sterilized antibiotic is added to the fermentor by aseptic transfer.

20 Fermentation Process. The process is started with a seed vial from the master cell bank (MCB).

The two-stage seed process begins by preparing the seed culture in a biological safety hood. 10-25 mL of sterile seed media is added aseptically to a presterilized flask. Filter-sterilized antibiotic solution is added to
25 the appropriate final concentration (20-100 µg/mL). The culture is then inoculated with ≥200 µL of bacterial culture from the MCB vial. The flask is covered and placed in an incubator shaker. The seed culture is incubated at 37°C with shaking at about 250 rpm for two to
30 six hours to develop the inoculum for the next stage. The next seed stage has the same antibiotic concentration, a volume of 1-10% of that used for the fermentation step, and is incubated similarly for two to eight hours.

Fermentation starts when the inoculum from the seed is aseptically transferred to the fermentor. The fermentation is supplemented with up to 100 $\mu\text{g/mL}$ antibiotic during the process to maintain selective pressure as cell density increases. Fermentation continues until an increase in dissolved oxygen indicates nutrient depletion, at which time the agitation is decreased and the culture cooled. After the temperature decreases to below 15°C , isolation steps are initiated. After fermentation, a sample of the culture is taken for a crude plasmid yield analysis, which is used to prepare for purification steps later in the process.

Isolation. The fermentation culture is centrifuged. The bacterial cell pellet is scraped from the centrifuge bowl(s) and transferred to presterilized 450 mL polypropylene bottles or resealable polyethylene bags for resuspension and mixing. The cells are washed once with an equal volume of wash buffer, centrifuged again and either stored at 2° to 8°C for no longer than 24 hours or stored at -20°C until the time of use.

D. Purification

Prepurification. The cells are gently resuspended with the same buffer used for washing cells with a quantity sufficient for a total volume of about 7-12 mL/g of wet cell weight (WCW). Resuspended cells are gently transferred to a larger bottle or vessel and about 7-12 mL of lysis solution are added per gram (WCW) of starting cells to rupture cells and to denature cellular protein and chromosomal DNA. After addition of the lysis solution, the contents are gently mixed and held at room temperature ($20-25^{\circ}\text{C}$) for about five minutes. Ice-cold neutralization solution is added, about 11-19 mL/g WCW, reducing the pH and precipitating cellular nucleic acids,

Buffers and solutions prepared for this and other steps are 0.2 micron filtered and stored either in pre-sterilized pyrex bottles or in sterile and endotoxin-free disposable bags. The water used is sterile water for irrigation (WFI).

Solid-liquid separation is performed initially via centrifugation. Centrifugation is performed at 0-8°C. The supernatant, containing fine colloidal particles, is 0.3 micron-filtered to remove the remaining precipitate, completing the solid-liquid separation. The final container used is presterilized, washed again with 0.5N sodium hydroxide and then triple-rinsed with WFI. The same treatment is applied to all product containers and transfer tubing used after this point with the exception of the containers used for pure bulk storage.

RNaseA stock solution, 100x concentration is stored at -20°C. RNA is digested after equilibrating the filtered alkaline lysis pool to room temperature and adding 0.01 v/v of RNase stock solution. The solution is incubated for a minimum of sixty minutes at a temperature of 30-45°C. The resulting solution is processed by chromatography immediately, or held overnight at 2 to 8°C in sterilized Pyrex containers.

Purification. The material is filtered through a 0.2 micron filter prior to chromatography. The supernatant containing plasmid, other cellular nucleic acids and protein is diluted three-fold with two volumes of WFI.

In the Q anion exchange step, the resin (Pharmacia Q high performance) is treated with 1 N NaOH for 30-35 minutes in the column as a precautionary measure. The column is conditioned with about 5 column volumes (CV) of Q and DEAE conditioning buffer, then equilibrated with about 5 CV of Q equilibration buffer (volume may be less

maximum of one mg of crude plasmid per mL of resin. After

the load, the column is washed with Q wash buffer for one additional CV after the column detector indicates output has leveled close to the baseline. The product is eluted with about 5 CV of elution buffer, with the actual peak on the chromatogram indicating when eluate collection starts and ends. The column is regenerated with about 5 CV each of the three Q regeneration solutions. The resin is stored in the column until the next use after pumping 5-10 CV of 0.01 N NaOH through the column, or cycled again.

10 The Q eluate may be stored at 2 to 8°C.

The RNA is checked using a crude plasmid analysis. If the ratio of the front RNA-containing peak to the second products containing peak is above a pre-set limit, a contingency alkaline hydrolysis and neutralization procedure is performed. Then 0.1 N NaOH is slowly added to the Q eluate with gentle mixing to achieve a final pH of 11.2-11.3. The pH of a sample of the treated solution is measured and recorded. The solution is held for about ten minutes at 20-25°C. Afterwards, 0.1 N HCl is added by slow addition with gentle mixing to neutralize the solution; the grid pH (between 7.5-8.0) is measured and recorded.

15
20

The pool is diluted about two-fold with WFI to give an appropriate salt concentration for the second purification step. As a precautionary measure in the DEAE anion exchange step, the resin (Tosohaas DEAE 650S) is treated with 0.1 N NaOH for 30-35 minutes in the column. The column is conditioned with about 5 CV of Q and DEAE conditioning buffer, then equilibrated with about 5 CV volumes of DEAE equilibration buffer. The column flow rate is a linear velocity of about 155 cm/hr for all steps. The feed is loaded to a maximum of 0.7 mg of crude plasmid per mL of resin. After the load, the column is washed with DEAE wash buffer for 5 CV. An additional CV of Q

25
30

is added to the column. The column is then washed with elution buffer with the beginning and end of peak

collection determined by the chromatogram. The column is regenerated with about 5 CV each of three regeneration solutions. The resin is stored until the next use after pumping 5-10 CV of 0.01 N NaOH through the column or
5 cycled again. The DEAE eluate is stored at 2 to 8°C.

The DEAE eluate is diluted two-fold with hydrophobic interaction chromatography (HIC)-conditioning solution. The HIC resin (Tosohaas Phenyl 650S) is treated with 0.1 N NaOH for 30-35 minutes in the column, as a precautionary
10 measure. The column is equilibrated with about 5 CV HIC of equilibration buffer. The column feed rate is a linear velocity of about 75 cm/hr for all steps. The feed is loaded to a maximum of 0.5 mg of crude plasmid per mL of resin and the flow through is collected. After the load,
15 the column is washed with one CV of HIC equilibration buffer after the detector indicates the chromatogram is close to baseline; the wash is collected with the flow-through. The column is regenerated with about 5 - 10 CV of each of the three regeneration solutions. The resin is
20 cycled again or stored until the next use after pumping 5-10 CV of 20% (v/v) ethanol through the column. The HIC eluate is stored at 2-8°C.

Alternatively, the purification process can be as described in U.S. Patent Application 60/022,157.

25 Myogenic Cell Cultures

Primary chicken myoblast cultures from breast muscles of day 11 white leghorn chick embryos were developed according to the protocol described in the art. Grichnik et al., *Nucleic Acids Research* 14:1683-1701 (1986).
30 Enriched myoblasts were plated at a density of 2×10^5 cells per 60 mm collagenized tissue culture dish.

Myogenic mammalian C₂C₁₂ and Sol 8 cells (1×10^5) were

DNA Transfer

Tissue culture cells were transfected with plasmid DNA by the calcium phosphate precipitation-glycerol shock protocol as known in the art. Wigler et al., *Cell* 14:725-731 (1978). A total of 10 μ g of DNA was used to transfect each 60 mm dish of tissue culture cells. Transfections were done in quadruplicate and with three different MVS-CAT-MLC plasmid preparations to control for variations in DNA quality and plating density of cells.

10 CAT Assay

After transfection two populations of cells, coinciding with replicating myoblasts and post-fusion myotubes were harvested, and assayed for CAT activity as described in the art. Gorman et al., *Molec. Cell. Biol.* 2:1044-1051 (1982). Cell pellets were lysed by repetitive freeze thaw cycles in 50 μ l of 250 mM Tris-HCl pH 7.5. The production of acetylated [14 C] chloramphenicol (0.5 μ Ci per assay, 57.8 mCi/mMol) was assayed for 90 minutes at 37° C. Acetylated chloramphenicol was monitored by autoradiography following thin layer chromatography on silica gel plates. Separated acetylated chloramphenicol spots were quantitated by scanning on a Betagen phosphoimager screen. Data was expressed as the percentage of converted [14 C] chloramphenicol per μ g cell protein. Protein concentration of cell extracts was determined by the method of Bradford, *Anal. Biochem.* 72:254-258 (1976)) at each time point to ensure uniformity in the assays.

Splicing of IGF-I Constructs

30 As described above, the pIG0100 construct was cloned to include the chicken skeletal actin promoter and intron

expression system does not use the actin 3' splice site,

instead it splices to a site in the IGF-I signal peptide sequence. The splicing has been confirmed by sequencing of RT-PCR products. It is believed that the resulting polypeptide has a 25 amino acid signal sequence, a form
5 which is naturally occurring in muscle and many other tissues. Adamo et al., 1994, *Adv. Exp. Med. Biol.* 343:1-11.

The pIG0552 construct contains the same upstream sequences as the pIG0100 construct with the human growth
10 hormone 3' UTR instead of the chicken skeletal α -actin 3' UTR. It is believed that the splicing of the pIG0552 product is the same as for the pIG0100 product. It has been confirmed by agarose gel analysis of RT-PCR products that the products from both constructs are the same size.

15 Activity of Expression Vector Constructs

To determine the efficacy of actin promoter/gene IGF-I hybrid genes in mouse myogenic cells the expression vector was studied using these genes in the background of mammalian C₂C₁₂ myoblasts by making a population of stable
20 transfected C₂C₁₂ myoblasts. The altered IGF-I expression levels were directly evaluated in these stable myoblast cell lines. Each IGF-I construction shown in Figure 3 was co-transfected with the drug selectable vector EMSV-Hygromycin into mouse C₂C₁₂ cells. After two weeks of
25 selection, a population of stable myoblasts was selected. A population of C₂C₁₂ myoblasts stably transfected only with EMSV-Hygromycin served as the controls. Visual inspection of the transfected myoblast revealed several insights into the role of IGF-I on muscle cell differentiation that
30 would not be obvious in transgenic mice. In general all of the myogenic cell lines containing IGF-I genes caused myoblasts in growth media (10% fetal calf serum) to

myoblasts fuse to form multinucleated myotubes over a

period of four days. At the same cell density per culture dish, myoblasts containing SK733IGF-I, SK202IGF-I-SK, SK733IGF-I-SK1 and SK733IGF-I-SK2 fused at least two-to-three days earlier than C₂C₁₂ or EMSV-Hygromycin control myoblasts.

In order to study the steady state accumulation of IGF-I mRNA in C₂C₁₂ myoblasts, equal amounts of total cellular RNA was isolated from stably transfected C₂C₁₂ myoblasts grown in growth media ("G") or differentiation media ("D"). The RNA was electrophoretically separated on denaturing agarose gels, transferred onto nylon filters and probed with uniformly ³²p labeled full length human IGF-I cDNA under standard hybridization techniques. The intensity of the autoradiographic signal on X-ray film provides a relative measure of mRNA accumulation, an overall index of combined transcriptional activity and mRNA stability of the expression vectors. The IGF-I mRNA in vector, SK202IGF-I-3'SVa did not accumulate in myotubes above myoblast levels. This is a typical expression activity. The SK733IGF-I vector contains the IGF-I 3'UTR. The IGF-I mRNA from this vector accumulated in myotubes but at levels substantially lower than SK202IGF-I-SK or SK733IGF-I-SK2. These latter two vectors contain the skeletal actin 3'UTR and 3'NCR. Since, the primary difference in these vectors is the 3'UTR, the increased stabilization of the RNA transcripts due to the skeletal 3'UTR accounts for about a 100-fold difference in RNA content.

In a similar assay, IGF-I was also produced at high levels from pIG0552 in C₂C₁₂ cells.

Measurement of Secreted Levels of IGF-I from IGF-I Gene Delivery by the Expression Vector

Media were grown, collected, and assayed for IGF-I (RIA grade). SK733IGF-I-SK2 is the

most effective construction to express IGF-I in muscle cells. IGF-I was assayed by both radioimmunoassays of tissue culture media and by immunoperoxidase staining of cells. Increased levels of IGF-I during the fusion of several muscle cultures was found. The comparison of levels from different expression vectors are shown in Table II. In control cultures, the level of IGF-I was in the range of 0.2-0.5 ng/ml. In comparison, vector SK733IGF-I-SK2 (pIG0100A or pIG0335) has levels of IGF-I at least one hundred times greater.

Table II

IGF-I Levels in Stably Transfected C₂C₁₂ Myoblasts

	Construction	IGF-I
	(ng/ml of media/4 days)	
15	SK202IGF-I-3'SVa	4.4
	SK733IGF-I	3.8
	SK733IGF-I-SK2	79.0
	Control C ₂ C ₁₂	0.5

In a similar manner, immunoperoxidase staining of myogenic cultures revealed the increased production of immunological reactive IGF-I in stable transfected myoblasts but not in the control EMSV-Hygromycin transfected myoblasts or in perfusion C₂C₁₂ cells. Antibodies against the A and D regions were used at dilutions of 1:1000. All of the transfected lines including SK202IGF-I were positively immunoperoxidase stained. Thus, it is clear that enhanced levels of IGF-I are being synthesized and exported from the stable myoblasts.

30 Insertion of Expression Vectors into Transgenic Mice

Transgenic mice carrying hIGF-I containing vectors

subsequent generations. Transgenics were identified by

polymerase chain reaction or Southern genomic DNA blotting analysis from tail cut DNA. Transgenics were tested for muscle specific expression of the transferred IGF-I vector by RNA blotting of total RNA isolated from several tissues. Independent transgenic mouse lines 5484, 5496, 5832, 5834 were generated with SK202IGF-I-3'SVa, containing the SV40 3' intron and poly A addition sequence. Mice from these strains were found to have weak expression, primarily in heart tissue, but very low levels were found in skeletal muscle and non-myogenic tissues such as the kidney and brain. Independent transgenic mouse lines 3357, 3359 generated with SK733IGF-I-3'SK2 (pIG0100A or pIG0335). Mice from these strains were found to have elevated expression levels of IGF-I. These levels are comparable to the endogenous mouse α -actin gene activity. These levels from SK733IGF-I-3'SK2 (pIG0100A or pIG0335) show at least 100-1000 fold greater accumulation of IGF-I mRNA in comparison to the levels produced by the SK202IGF-I-3'SVa vector. The addition of the skeletal α -actin 3'UTR and 3' flanking region allowed for a preferential increase in IGF-I RNA in skeletal muscle rather than cardiac. Thus, the 3'UTR and 3' NCR of skeletal α -actin enhance muscle specific gene expression.

Mice from these strains demonstrated increased muscle mass and reduced percentages of body fat as compared to the parental types. The use of human IGF-I in the mouse demonstrates the cross-species applicability of this particular gene.

In addition, by providing contiguous 3' NCR, IGF-I is buffered against outside genomic sequences and is thus more protected from position effects, when integrated into the genome. Also, by providing natural terminating sequences, the additional regulatory sequences that mark the transcriptional domain of skeletal α -actin prevent

Presence of 3'NCR sequence allows for a single copy of the

integrated vector to produce 40-50% of the transcriptional activity of the endogenous sequences.

Somatic Gene Transfer to Skeletal Muscle In Vivo

To demonstrate an effect of the IGF-I encoding
 5 vectors as used in in vivo gene therapy, vectors were
 injected into adult muscle for the express purpose of
 expression of a particular polypeptide. The growth
 hormone-deficient mouse strain, *little*, was used in these
 studies. Vector SK733IGF-I-SK2 (pIG0100A or pIG0335), or
 10 control vector SKSK, was pelleted by sedimentation, dried
 under vacuum and punctured into the quadriceps muscle (20
 μ g/pellet - 3 pellets/muscle) of 2 sets of 6 *little* mice.
 The entire muscle from each animal that received an
 inoculation was removed 2 weeks following introduction of
 15 the DNA and assayed for IGF-I protein in the tissue. The
 amount of IGF-I in each tissue was assayed by using a
 radioisotopic assay. A slight yet significant ($p>0.05$)
 increase was observed in IGF-I expression (Table III) from
 4.2 ng to 6.9 ng IGF-I/100 μ g total protein of muscle
 20 lysate in mice with vector only (no IGF-I) for mice with
 the vector SK733IGF1-3'SK.

TABLE III

IGF-I Levels in Tissues of IGF-I Vector-Injected *little* MICE

	Mouse#	Strain	Plasmid	IGF-I (ng/100ug)
25	776	<i>little</i>	PSKSK	4.2
	777	<i>little</i>	PSKSK	4.2
	778	<i>little</i>	PSKSK	4.5
	779	<i>little</i>	PSKSK	3.9
30	780	<i>little</i>	PSKSK	3.9
	781	<i>little</i>	PSKSK	4.2
	Average			4.15±0.21
	782	<i>little</i>	pSK733IGFSK	4.5
			SK733IGFSK	6.9
	783	<i>little</i>	SK733IGFSK	6.9
	784	<i>little</i>	SK733IGFSK	6.9
	785	<i>little</i>	SK733IGFSK	6.9
	786	<i>little</i>	SK733IGFSK	6.9
	787	<i>little</i>	pSK733IGFSK	7.0
	Average			6.88±1.08

Intramuscular Injections of a IGF-I Myogenic Vector in Diabetic Rats.

The effect of intramuscular injections of a muscle-specific DNA vector carrying the human insulin-like growth factor-I ("IGF-I") on diabetes-induced alterations in body and muscle weights, plasma glucose levels and the mRNA level from the injected IGF-I vector was examined. An IGF-I expressing vector was chosen for this work since injections of recombinant IGF-I have been shown to have anabolic effects in a number of models of cachexia.

Diabetes was induced in male Sprague-Dawley rats (175200 g) with intravenous injections of streptozotocin (STZ; 55 mg/kg) dissolved in sodium citrate buffer (0.05 M, pH 4.5). Control non-diabetic animals were age, weight and sex matched and received equal volume injections of vehicle. Diabetes was confirmed by the onset of hyperglycemia, glucosuria, and reduced rate of growth. Three days following STZ administration, non-fasted animals were anesthetized with pentobarbital (50 mg/kg) and blood samples were obtained by cardiac puncture. Blood was transferred to EDTA-containing tubes, centrifuged at 3000 x g for 15 min and stored at -70°C. The gastrocnemius was injected bilaterally following direct visualization of the muscle via a cutaneous incision. The right gastrocnemius muscle of individual rats was injected with either 0, 50, 200, or 800 µg of IGF-I vector in 200 µl of isotonic saline solution. The contralateral (left) gastrocnemius received 200 µl injections of isotonic saline. The IGF-I vector used in this series of experiments was Sk-733-IGF-I-Sk2 as described above. Six days following intramuscular injection of muscle-specific vector, the animals were deprived of food (12-16 hrs) followed by euthanization by decapitation. Blood was then collected and the entire gastrocnemius muscle was removed.

weight dosage groups were matched on pre-vector injection

body weight and only diabetic animals were included in the analysis. The plasma glucose criteria for inclusion in the analysis was a non-fasting plasma glucose level greater than 300 mg/100 ml. Pre-vector injection body weights were matched by only including animals with body weights between 175-195 gm. For the analysis of vector effects on plasma glucose levels the groups were matched on pre-vector injection plasma glucose levels. Intramuscular injections of IGF-I vector result in increased body weight (Mean \pm SD; Vehicle Only = 181.37 \pm 6.17; 50 μ g = 193.43 \pm 5.71; 200 μ g = 186.6 \pm 8.01; 800 μ g = 191.14 \pm 7.54). This body weight increase is statistically significant at the 50 and 800 μ g, but not the 200 μ g, dose level (a priori t-test: Control vs. 50 μ g, t = 3.57, df = 12; Control vs. 200 μ g, t = 1.17, df 10; Control vs. 800 μ g, t = 2.29, df = 12).

In addition to increasing body weight IGF-I vector injections also increase the weight of the vector injected gastrocnemius (Mean \pm SD; Vehicle Only = 1.00 \pm 0.08; 50 μ g 1.10 \pm 0.07; 200 μ g = 1.07 \pm 0.03; 800 μ g = 1.09 \pm 0.05) This increase in vector injected gastrocnemius weight is statistically significant at the 50 and 800 μ g, but not the 200 μ g, dose level (a priori t-test: Control vs. 50 μ g, t = 2.32, df = 12; Control vs. 200 μ g, t = 1.75, df 10; Control vs. 800 μ g, t = 2.32, df = 12). The weight of the contralateral gastrocnemius was also increased but this increase did not reach statistical significant (Mean \pm SD; Vehicle Only = 1.00 \pm 0.07; 50 μ g = 1.07 \pm 0.06; 200 μ g = 1.05 \pm 0.01; 800 μ g = 1.08 \pm 0.06; a priori t-test: Control vs. 50 μ g, t = 1.72, df = 12; Control vs. 200 μ g, t = 1.43, df 10; Control vs. 800 μ g, t = 2.11, df = 12).

The level of expression of the injected IGF-I vector was determined by isolating the total RNA from the gastrocnemius muscle and subjecting it to reverse transcription using DNAase and subjected to reverse transcription using

oligo-dT as a primer in order to generate cDNA replicas of mRNA. The cDNA was then reacted with IGF-I specific primers in a polymerase chain reaction to estimate the level of expression of mRNA in the original muscle sample.

- 5 The bands corresponding to IGF-I-specific primer amplified products were detected. The data indicates that the IGF-I vector IGF-I construct is being expressed at significant levels in the injected muscle. The control muscle showed no expression of human IGF-I.

- 10 Relative to the Control group fasting plasma glucose levels in the 50 μ g IGF-I vector dose group were significantly lower (Mean \pm SD; Vehicle Only = 277.14 \pm 113.65; 50 μ g = 155.42 \pm 37.54; 200 μ g = 224.06 \pm 89.21; 800 μ g = 216.57 \pm 100.55 mg/100 ml). (a priori t-test: 15 Control vs. 50 μ g, t = 3.23, df = 12; Control vs. 200 μ g, t = 1.04, df 17; Control vs. 800 μ g, t = 1.09, df = 16).

- These findings indicate that intramuscular injections of IGF-I vector (SK-7331-IGF-I-SK2) reduce diabetic hyperglycemia and increase body and muscle weight 20 suggesting that IGF-I expression levels are sufficient to trigger an anabolic effect. The finding that the vector injected, but not the contralateral, gastrocnemius significantly increases in weight suggests a difference in local IGF-I concentration in the two muscles.

- 25 Effect of Substitution of the hGH 3' UTR for the skeletal actin 3' UTR in skeletal actin - IGF-I transgenes on circulating concentrations of hIGF-I in transgenic mice

- Transgenic mice containing the skeletal actin-IGF-I transgenes described in Figure 15 were generated. Serum 30 samples were obtained and assayed for hIGF-I. Results (Table IV) clearly demonstrate that transgenes containing the hGH 3' UTR elicit increased concentrations of hIGF-I in skeletal muscle relative to transgenes containing the skeletal

actin 3' UTR. The results indicate that the 5' UTR appear to have little or no effect.

Table IV

Human IGF-I concentrations in serum of mice carrying skeletal actin - IGF-I transgenes.

	Transgene	Animal ID	hIGF-I (ng/ml)
5	SISII	2813	3.0
	448ISK	8219	6.5
	448ISK	8226	ND ¹
	448ISK	8230	ND
	SIGh	2950	292.9
10	SIGh	5196	30.3
	GIG	2338	253.7
	GIG	2360	94.5
	Non-transgenic control		ND
15	¹ ND - Not detectable (assay sensitivity is approximately 1 ng/ml).		

As is shown by the data in the table, the GH 3' UTR sequences result in greatly enhanced serum concentrations (i.e., enhanced secretion) of the encoded polypeptide as compared to the use of 3' sequences, such as skeletal actin 3' UTR, which provide higher retention of the product in the tissue. Thus, selection of 3' UTR sequences having appropriate secretion or retention promoting properties provides the ability to control the localization of the encoded product.

Enhanced Vector Expression in Intact Muscle

Intact plasmid DNA in a sterile 20% sucrose solution (wt/vol) can be injected into mature avian or mammalian muscle. Following a single injection the vector DNA is stable for at least 30 days as a non-degraded, extrachromosomal, circular DNA in muscle.

greater than 99% of the injected DNA is degraded in

muscle under the Wolff protocol (Wolff, et al, *BioTechniques* 11:4374-485 (1991)). This protocol can be improved by increasing the uptake of plasmid DNA into muscle and reducing vector degradation. The procedure of the present invention can use expression vector DNA coated with the relevant transcriptional regulatory factors, the human serum response factor and other human associated nuclear proteins, such as histone, and transcription initiation factors to enhance uptake and stability. The regulatory proteins protect the DNA against muscle nucleases and facilitate the uptake of the protein coated DNA into myogenic nuclei.

The expression vector forms a protein/DNA complex by the sequence specific binding of the serum response factor with the inner core CCXXXXXXGG (where X can be either A or T; SEQ ID NO. 6) of the serum response element and by the addition of histone. The interaction with the inner core of the promoter facilitates myogenic cell type restricted expression of the skeletal α -actin gene. The serum response factor, transcription initiation factor, transregulatory factor and histones are added to the expression vector by an in vitro binding reaction to form a reconstituted protein/DNA complex.

25 Coating the Expression Vector System

A specific formulation involves coating the vector with elements of the transcription initiation complex and histone. This formulation is used both to enhance delivery of the vector to the cell and to enhance expression of the vector within the cell.

The following protocol was used to bacterially express and purify human serum response factor (SRF).

1. Expression of SRF in E. coli

SRF was expressed in E. coli strain BL21 (DE3) using the pET21a vector (Novagen) under the control of the (isopropyl-B-D-thiogalactopyranoside) induction. (Manak

et al., *Genes and Development* 4:955-967 (1990)). *E. coli* BL21 harboring the plasmid was grown at 37°C to an OD₆₀₀ of 0.4 in TYP medium supplemented with ampicillin (50 µg/ml). Synthesis of SRF was then induced with 1mM IPTG for 2.0 hr, after which cells were spun down, washed once in TE buffer (10 mM Tris-HCl, 1mM EDTA, pH 7.0) and resuspended in a 40X packed cell volume and dialyzed against (10 mM HEPES [N-2 hydroxyethylpiperzine-N-2-ethansulfonic acid, pH 7.4], 60 mM KCl, 1mM 2-mercaptoethanol 0.5 mM EDTA, 0.5 mM phenylmethanysulfonyl fluoride and 10% glycerol). Cells were disrupted on ice by sonication. The lysate was clarified by centrifugation (15,000 xg for 20 min.) and the high speed supernatant containing overexpressed SRF was stored at -80°C. Partial purification of SRF was done as follows. A 10 ml amount of the lysate was applied to a 10 ml phosphocellulose column equilibrated with column buffer (same as dialysis buffer as described above) and 0.05% Nonidet P-40. The flow through fractions were collected and applied to a 5-ml heparin agarose column. The column was washed with 0.35 M KCl and SRF was eluted with 0.5 M KCl. SRF was then dialyzed and stored at -80°C.

Approximately, a ratio by weight of 5 to 1 SRF protein to expression vector DNA was allowed to incubate together in a solution containing 10 mM Tris-HCl (pH 8.0, 0.1 mM EDTA, 2mM dithiothreitol, 5% glycerol plus 100 mM KCl. The binding of SRF to the actin promoter has been verified by DNA binding assays and by nuclease footprint protection assays as shown in the art.

Transcription initiation factors such as the TATA box protein (TBP) and other initiation factors such as TFIIB, E and F are eluted from purified HeLa cell nuclei

1. The following factors are eluted from purified HeLa cell nuclei:

initiation factors are mixed together with the SRF-DNA

plasmid at a ratio of 10 parts protein to one part SRF-DNA to help form a preinitiation complex which is dialyzed for 24 hours. Finally, a crude histone preparation which is stripped from HeLa nuclei in 6M urea, 2M NaCl is dialyzed against low salt dialysis buffer. The full complement of histone are slowly added to a final ratio of 1 to 1 (histone to the SRF-protein DNA complex) to form nucleosome particles over nonprotected DNA. The addition of histone will protect regions of DNA to a greater extent than naked DNA from cellular nucleases.

The nucleoprotein complex is then further formulated with a lipid base, nonaqueous base and/or liposomes for direct injection into muscle. Because of the abundance of specific transcription factors, which contain nuclear targeting sequences, expression vector DNA is readily delivered, and taken up into muscle nuclei.

The vector can also be prepared in a formulation with other DNA binding compounds. For example, the vector can be prepared with polyvinyl pyrrolidone (PVP). PVP is a synthetic polymer consisting of linear 1-vinyl-2-pyrrolidone groups. PVP is commercially available with various degrees of polymerization and molecular weights. Pharmaceutical grade PVP is marketed under the trade names Plasdone (International Specialty Products, ISP) and Kollidon (BASF). ISP describes the typical properties of Plasdone C-30 in its product literature. Plasdone C-30 has a weight average molecular weight of 50,000 g/mol.

PVP is found to interact with DNA by hydrogen bonding. PVP is also found to protect DNA in vitro from nuclease (DNase 1) degradation. Reporter genes (CMV-CAT

EXPOSURE TO DNA RESULTS SHOWED THAT DNA + PLASDONE 1 mg/mL in 5% PVP in 150 mM NaCl led to the highest

enhancement of gene expression over DNA formulated in saline. The levels of gene expression using lower molecular weight PVP (Plasdone C-15) were approximately 2-fold lower than levels of gene expression using formulations made with Plasdone C-30. When rat tibialis muscles were injected with DNA formulated in either saline or 5% PVP (Plasdone C-30), immunochemical staining for β -galactosidase revealed that the staining was more widely distributed in muscles treated with the formulated DNA. The staining also showed that the PVP formulation resulted in an increase in the number of cells expressing β -gal and that these cells were distributed over a larger area as compared to DNA injected in saline. It is suggested that the increased tissue dispersion of DNA using PVP formulations is due to a hyper-osmotic effect in the muscle. DNA (3 mg/mL) in 5% PVP (Plasdone C-30) in 150 mM NaCl exerts an osmotic pressure of 341 ± 1 mOsm/kg H_2O .

An exemplary formulation of the hIGF-I plasmid is a three-vial system, with product components to be mixed just prior to use. The product components are:

1. Human IGF-I plasmid in sterile water;
2. Lyophilized PVP (polyvinylpyrrolidone; Plasdone C-30, Povidone U.S.P.); chemical formula $(C_6H_9NO)_n$;
3. 115 mM sodium citrate buffer (pH 4) in 5% NaCl.

The expression vector can also be delivered as described below.

30 Administration

Administration as used herein refers to the route of introduction of a vector or carrier of DNA into the

invention can be used for treating disease by

administration of the vector to the body in order to establishing controlled expression of any specific nucleic acid sequence within tissues at certain levels that are useful for gene therapy.

- 5 The preferred means for administration of vector and use of formulations for delivery are described above. The preferred embodiment is by direct injection using needle injection or hypospray.

- 10 The route of administration of any selected vector construct will depend on the particular use for the expression vectors. In general, a specific formulation for each vector construct used will focus on vector uptake with regard to the particular targeted tissue, followed by demonstration of efficacy. Uptake studies
15 will include uptake assays to evaluate cellular uptake of the vectors and expression of the tissue specific DNA of choice. Such assays will also determine the localization of the target DNA after uptake, and establishing the requirements for maintenance of steady-
20 state concentrations of expressed protein. Efficacy and cytotoxicity can then be tested. Toxicity will not only include cell viability but also cell function.

- Muscle cells have the unique ability to take up DNA from the extracellular space after simple injection of
25 DNA particles as a solution, suspension, or colloid into the muscle. Expression of DNA by this method can be sustained for several months.

- Delivery of formulated DNA vectors involves incorporating DNA into macromolecular complexes that undergo
30 endocytosis by the target cell. Such complexes may include lipids, proteins, carbohydrates, synthetic organic compounds, or inorganic compounds. The characteristics of the complex formed with the vector

 The complexes may be formulated with ligands or ligand which interact with specific receptors on the

surface or interior of the cell. Other elements of the formulation function to enhance entry into the cell, release from the endosome, and entry into the nucleus.

Delivery can also be through use of DNA

5 transporters. DNA transporters refers to molecules which bind to DNA vectors and are capable of being taken up by epidermal cells. DNA transporters contain a molecular complex capable of noncovalently binding to DNA and efficiently transporting the DNA through the
10 cell membrane. It is preferable that the transporter also transport the DNA through the nuclear membrane. See, e.g., the following applications all of which (including drawings) are hereby incorporated by reference herein: (1) Woo et al., U.S. Serial No.
15 07/855,389, entitled "A DNA Transporter System and Method of Use,, filed March 20, 1992, now abandoned; (2) Woo et al., PCT/US93/02725, International Publ. WO93/18759, entitled "A DNA Transporter System and method of Use", (designating the U.S. and other
20 countries) filed March 19, 1993; (3) a continuation-in-part application by Woo et al., entitled "Nucleic Acid Transporter Systems and Methods of Use", filed December 14, 1993, U.S. Serial No. 08/167,641; (4) Szoka et al., U.S. Serial No. 07/913,669, entitled "Self-Assembling
25 Polynucleotide Delivery System", filed July 14, 1992 and (5) Szoka et al., PCT/US93/03406, International Publ. WO93/19768 entitled "Self-Assembling Polynucleotide Delivery System", (designating the U.S. and other countries) filed April 5, 1993.

30 Transfer of genes directly into muscle has been very effective. Experiments show that administration by direct injection of DNA into muscle cells results in expression of the gene in the area of injection.

unintegrated extrachromosomal state. This means of transfer is the preferred embodiment.

Another preferred method of delivery involves a DNA transporter system. The DNA transporter system consists of particles containing several elements that are independently and non-covalently bound to DNA. Each element consists of a ligand which recognizes specific receptors or other functional groups such as a protein complexed with a cationic group that binds to DNA. Examples of cations which may be used are spermine, spermine derivatives, histone, cationic peptides and/or polylysine. One element is capable of binding both to the DNA vector and to a cell surface receptor on the target cell. Examples of such elements are organic compounds which interact with the asialoglycoprotein receptor, the folate receptor, the mannose-6-phosphate receptor, or the carnitine receptor. A second element is capable of binding both to the DNA vector and to a receptor on the nuclear membrane. The nuclear ligand is capable of recognizing and transporting a transporter system through a nuclear membrane. An example of such ligand is the nuclear targeting sequence from SV40 large T antigen or histone. A third element is capable of binding to both the DNA vector and to elements which induce episomal lysis. Examples include inactivated virus particles such as adenovirus, peptides related to influenza virus hemagglutinin, or the GALA peptide described in the Skoka patent cited above.

Administration may also involve lipids. The lipids may form liposomes which are hollow spherical vesicles composed of lipids arranged in unilamellar, bilamellar, or multilamellar fashion and an internal aqueous space for entrapping water soluble compounds, such as DNA,

liposomes may be formed by a variety of methods including

the following:

1. cationic lipids and complexes containing DOPE which

interact with DNA and with the membrane of the target cell to facilitate entry of DNA into the cell.

Gene delivery can also be performed by transplanting genetically engineered cells. For example, immature muscle cells called myoblasts may be used to carry genes into the muscle fibers. Myoblasts genetically engineered to express recombinant human growth hormone can secrete the growth hormone into the animal's blood. Secretion of the incorporated gene can be sustained over periods up to 3 months.

Myoblasts eventually differentiate and fuse to existing muscle tissue. Because the cell is incorporated into an existing structure, it is not just tolerated but nurtured. Myoblasts can easily be obtained by taking muscle tissue from an individual who needs gene therapy and the genetically engineered cells can also be easily put back without causing damage to the patient's muscle. Similarly, keratinocytes may be used to deliver genes to tissues. Large numbers of keratinocytes can be generated by cultivation of a small biopsy. The cultures can be prepared as stratified sheets and when grafted to humans, generate epidermis which continues to improve in histotypic quality over many years. The keratinocytes are genetically engineered while in culture by transfecting the keratinocytes with the appropriate vector. Although keratinocytes are separated from the circulation by the basement membrane dividing the epidermis from the dermis, human keratinocytes secrete into circulation the protein produced.

Delivery may also involve the use of viral vectors. For example, an adenoviral vector may be constructed by replacing the E1 region of the virus genome with the

will package this gene into an infectious virus

particle. Virus from this cell may then be used to infect tissue *ex vivo* or *in vivo* to introduce the vector into tissues leading to expression of the gene in the nucleic acid cassette.

- 5 The chosen method of delivery should result in expression of the gene product encoded within the nucleic acid cassette at levels which exert an appropriate biological effect. The rate of expression will depend upon the disease, the pharmacokinetics of
10 the vector and gene product, and the route of administration, but should be between 1-1000 mg/kg of body weight/day. This level is readily determinable by standard methods. It could be more or less depending on the optimal dosing. The duration of treatment will
15 extend through the course of the disease symptoms, possibly continuously. The number of doses will depend upon disease delivery vehicle and efficacy data from clinical trials.

Animal Safety/Toxicology Studies

- 20 A. Acute 7-day and Subchronic 28-day Toxicity Studies

Acute 7-day and subchronic 28-day toxicity studies were conducted in dogs in compliance with the Good Laboratory Practice (GLP) Regulations of the United
25 States Food and Drug Administration (21 CFR Part 58). The test articles and vehicle used in these studies were manufactured under cGMP procedures. Dogs were used because the mature human IGF-I (hIGF-I) which is expressed by the plasmid is identical to canine IGF-I.

- 30 The objective of the 7-day acute study was to investigate the potential acute toxicity of hIGF-I plasmid following a single intravenous injection in the
35 ... of ... each consisting of two

... polyvinylpyrrolidone (PVP), at dosage levels of 0.1,

1.0, and 12.0 mg/kg. The highest dose level was selected based on the maximum solubility of the test article in the vehicle and the total volume allowed for injection in dogs. The low dose corresponds to the
5 minimum effective dose in preclinical animal studies in rodents.

A control group received the vehicle (PVP) only at the highest dose used with the test article. Two additional recovery groups (two males and two females in
10 each) treated with the highest dose of test article and control animals were kept for another week. The dogs were sacrificed on day 8 after injection, and the recovery groups were sacrificed on day 15 after injection.

15 An intravenous route of administration was used to mimic a "worst-case" scenario of systemic exposure of the test article. Mortality checks were performed twice daily throughout the study, and detailed examinations for clinical signs were performed hourly for the first
20 four hours after dosing and daily during the observation period. Body weights were measured twice weekly during the last week of acclimation and throughout the observation period. Laboratory investigations (hematology, clinical biochemistry and urinalysis) were
25 performed during the pretreatment period and on samples collected on days 2, 7, and 14 for all surviving animals. A complete necropsy was conducted on all animals, and selected organs including muscles were weighed.

30 There were neither abnormal clinical signs nor effects on body weight, food consumption, hematology, clinical biochemistry or urinalysis parameters. In addition, there were no differences in organ weights or

observed clinical signs. The animals were observed for approximately two hours and were consistent

with previous reports of histamine release in response to PVP observed in dogs. Thus, the signs were attributed to the PVP present in the dose formulations and not to the hIGF-I plasmid.

5 The objective of the subchronic study was to investigate the potential toxicity of hIGF-I plasmid during weekly intramuscular injection to beagle dogs for four weeks, followed by a four week recovery period. The intramuscular route is the intended route of
10 administration in humans. Dogs were injected intramuscularly once weekly for four weeks with 0.1, 1.0, and 6.0 mg/kg. Each group consisted of three dogs per sex. Additional recovery groups (two dogs/sex) at the highest dose and control animals were observed for
15 an additional 28 days. Mortality checks were performed at least twice daily throughout the study, and examinations for clinical signs of ill-health or reaction to treatment were performed at least twice daily following initiation of treatment. Individual
20 body weights were determined on the day of randomization and weekly during the treatment and recovery periods. Food consumption was measured daily during the treatment and recovery periods. Ophthalmoscopy was performed once prior to the start of treatment and again during the
25 last week of treatment (Week 4) and the last week of the recovery period (Week 8). Cardiovascular studies (electrocardiograms and systolic blood pressure measurements) and laboratory investigations (hematology, clinical biochemistry and urinalysis) were performed
30 once prior to the start of treatment and again during weeks 4 and 8. In addition, serum samples were obtained on the same occasions and stored for possible future analysis. A complete necropsy was conducted on all

There were neither abnormal clinical signs nor effects on body weight, food consumption, blood pressure, electrocardiograms, hematology, clinical biochemistry, urinalysis parameters, or ocular changes which were considered related to hIGF-I plasmid. As in the acute study, clinical signs consistent with histamine release were observed in control and high dose animals following administration of the control or test article. In response to occasional (4 out of 16) severe reactions, epinephrine was administered intravenously to prevent mortality. As before, these reactions were attributed to the PVP present in the test article and not to hIGF-I plasmid.

A pilot exploratory study conducted in two dogs confirmed that the observed clinical signs were due to histamine release. The dogs were injected intramuscularly with the vehicle at the high dose level (6 mg/kg) that elicited the clinical signs of histamine release. One of the dogs was pretreated with an H₁ histamine receptor blocker, diphenhydramine hydrochloride (Benadryl[®], 1 mg/kg). Both dogs developed the clinical signs, and pretreatment with the histamine antagonist did not abrogate the signs. Blood samples were analyzed for histamine levels, and they were approximately 100-fold or more higher than pretreatment levels in both dogs. These results suggest that the dosage of histamine blocker was inadequate. We believe that the effects seen in dogs are species specific and are unique to dogs. Experience with PVP used as a blood expander has not shown similar clinical signs in humans. There were no differences in organ weights or gross or histopathological findings which were considered to be related to hIGF-I plasmid.

Clinical signs consistent with histamine release

observed in control and high dose animals were attributed to the polyvinylpyrrolidone present in the dose formulations and not to hIGF-I plasmid.

B. Assay of Canine Serum for Anti-hIGF-I and
Anti-DNA Antibodies

5 Serum samples obtained from dogs treated with hIGF-I plasmid in the subchronic (28 day) toxicity study were assayed for the presence of antibodies to rhIGF-I and double stranded (ds) DNA. Dogs were injected
10 intramuscular with hIGF-I plasmid at dosages of 0 (vehicle control), 0.1, 1.0 and 12.0 mg/kg every 7 days for a period of 28 days. Serum samples (see outline in Table V) were obtained prior to the initiation of dosing (pre-bleed), at the end of dosing (day 27), and after a
15 28 day recovery phase (day 55). A total of 76 samples were assayed.

75

Table V

Outlines of serum samples assayed for antibodies
to hIGF-I and to DNA

	<u>Dosage</u>	<u>Pre-bleed</u>	<u>Day 27</u>		<u>Day 55</u>	
			F	M	F	M
5	sex	M				
	Vehicle	5 ^a	5	5	3	
	control	5				3
	0.1 mg/kg BW	3	3	3		
		3				
10	1.0 mg/kg BW	3	3	3		
		3				
	12.0 mg/kg BW	5	5	5	3	
		5				3

^aNumbers represent the number of serum samples that were collected and assayed.

Antibodies to rhIGF-I were assayed using standard
15 ELISA procedures. Results indicated that serum samples from treated dogs contained no detectable antibodies to rhIGF-I. Antibodies to dsDNA were assayed using an ELISA kit (The Binding Site, Inc., Birmingham, U.K.) designed to quantitate antibodies to dsDNA in human
20 serum and was modified to quantify antibodies in dog serum. The anti-human IgG HRP conjugate was replaced with rabbit anti-dog IgG HRP conjugate as the second antibody. Results indicated that no serum samples from treated dogs contained detectable antibodies to ds DNA.

25 Pharmacokinetics/Biodistribution Studies

A. Time-Course of Expression of rhIGF-I in Rat

30 intramuscular injection of hIGF-I plasmid. Human IGF-I

plasmid formulated in polyvinyl pyrrolidone was injected bilaterally into tibialis anterior muscles (150 μ g DNA/muscle) of male Fisher 344 rats (approximately 125 g BW). Rats were randomly divided into two groups with 5 animals in one group receiving every other day injections of the immunosuppressant cyclosporine A (5 mg/kg BW) into the gluteus muscle for the duration of the experiment. Rats from each group were sacrificed at 10 24 hours, 48 hours, 7 days, 14 days, and 28 days following injection of hIGF-I plasmid (n=5-6 rats/group/time point). Tibialis anterior muscles were harvested at these times and analyzed for expression of rhIGF-I by immunoradiometric assay (Diagnostic Systems Laboratories, Inc., Webster, TX).

15 Reverse transcriptase PCR analysis of total RNA from injected muscles did not reveal expression of hIGF-I mRNA at 24 or 48 hours post-injection. Expression of hIGF-I mRNA was observed at days 7, 14, and 28. Results for intramuscular content of rhIGF-I at 7, 14, and 28 20 days post-injection show that intramuscular content of rhIGF-I was similar at approximately 1.5-2.5 ng/g muscle between days 7 and 14 post-injection and decreased to approximately 35 percent of day 7 values by 28 days post-injection. Treatment with cyclosporine A to 25 suppress the immune response did not affect ($p>.10$) intramuscular rhIGF-I content nor were antibodies to hIGF-I detected in serum of rats not receiving cyclosporine A treatment at 28 days post-injection. Together, these results suggest that the decrease in 30 intramuscular rhIGF-I was not due to a host immune response. Human IGF-I was not detected in serum samples from injected rats at any time point.

pharmacokinetics and tissue distribution of hIGF-I

5 hIGF-I plasmid. Two groups of Hartley guinea pigs were each injected once with either a low dose (0.1 mg/kg) or a high dose (1.5 mg/kg) of hIGF-I plasmid formulated in 5% PVP by intramuscular or intravenous injections (50 males and 50 females per route of administration).

Five animals per sex from each treatment group were sacrificed at the following time intervals: 30 minutes, 1 hour, 6 hours, 12 hours, 1 day, 2 days, 1 week, 4 weeks and 3 months. As a control, one group of 10 male and 10 female guinea pigs per route of administration received the vehicle at the same volume/weight ratio as the high dose-treated group.

Gonads, lymph nodes, liver, spleen, kidney, lungs, heart, brain, bone marrow, muscle, and blood were collected at each sacrifice point. The blood was stored at 5°C, and the tissues were frozen in liquid nitrogen and stored at -70°C. DNA from blood samples was analyzed for the presence of the human IGF-I plasmid using a sensitive polymerase chain reaction (PCR) assay. If the plasmid was detected in the blood, the selected tissues were presumed to be positive and were not analyzed. If the plasmid was not detected in the blood sample, the DNA from the tissue samples was amplified in duplicate. One sample of each duplicate was spiked with the test plasmid at a copy number near the limit of detection to demonstrate the absence of any polymerase chain reaction (PCR) inhibition. Samples from animals treated using the high dose intramuscular and the intravenous routes have not yet been analyzed. Any

\mathbb{R}^n

sacrificed through the second day following test article

dosing indicated the presence of the DNA plasmid. By day 7 after dosing, the plasmid had disappeared from the blood. PCR analysis of the samples (gonads, kidneys, liver, heart, and muscle tissues) from animals from the
5 animals sacrificed three months after intramuscular injection of a low dose of hIGF-I plasmid (0.1 mg/kg) indicated elimination of most of the test plasmid at the injection site and in the peripheral systemic locations.

No clinical signs of toxicity were observed in any
10 animal of either sex during the course of the study. All animals survived to the scheduled sacrifices. The animals for which terminal body weights were recorded (animals sacrificed after day 1) gained weight from the time of dosing to the time of sacrifice. There were no
15 apparent significant chemically-related effects on body weight. Gross examination of selected tissues at necropsy revealed no abnormal findings at any time point with one exception. Brown foci on all lobes of the
20 lungs were observed in one low dose female; however, this finding was not thought to be related to treatment with the test article.

In general, the data indicated that the hIGF-I plasmid is eliminated after three months. Out of a total of fifty tissues analyzed from ten animals given
25 intramuscular injections of the low dose plasmid, only three positive signals were noted: one ovary, one liver and one muscle. The signals were sporadic and did not appear to be tissue-specific. All negative control tissues gave negative results.

30 Therefore, based on the complete lack of test article-related mortality, clinical signs of toxicity, effects of body weight, or gross lesions at necropsy three months following exposure, the test article (as

Cell Transfection and Transformation

One aspect of the present invention includes cells transfected with the vectors described above. Once the cells are transfected, the transformed cells will
5 express the protein or RNA encoded for by the nucleic acid cassette. Examples of proteins include, but are not limited to polypeptide, glycoprotein, lipoprotein, phosphoprotein, or nucleoprotein.

The nucleic acid cassette which contains the
10 genetic material of interest is positionally and sequentially oriented within the vectors such that the nucleic acid in the cassette can be transcribed into RNA and, when necessary, be translated into proteins or polypeptides in the transformed cells.

15 A variety of proteins can be expressed by the sequence in the nucleic acid cassette in the transformed cells. Those proteins which can be expressed may be located in the cytoplasm, nucleus, membranes (including the plasmalemma, nuclear membrane, endoplasmic reticulum
20 or other internal membrane compartments), in organelles (including the mitochondria, peroxisome, lysosome, endosome or other organelles), or secreted. Those proteins may function as intracellular or extracellular structural elements, ligand, hormones, neurotransmitter,
25 growth regulating factors, differentiation factors, gene-expression regulating factors, DNA-associated proteins, enzymes, serum proteins, receptors, carriers for small molecular weight organic or inorganic compounds, drugs, immunomodulators, oncogenes, tumor
30 suppressor, toxins, tumor antigens, or antigens. These proteins may have a natural sequence or a mutated sequence to enhance, inhibit, regulate, or eliminate their biological activity. A specific example of a

RNA may be used to inhibit translation, as an antisense inhibitor of gene

expression, as a triple-strand forming inhibitor of gene expression, as an enzyme (ribozyme) or as a ligand recognizing specific structural determinants on cellular structures for the purpose of modifying their activity.

5 Specific examples include RNA molecules to inhibit the expression or function of prostaglandin synthase, lipo-oxenganse, histocompatibilty antigens (class I or class II), cell adhesion molecules, nitrous oxide synthase, β_2 microglobulin, oncogenes, and growth factors.

10 The compounds which can be incorporated are only limited by the availability of the nucleic acid sequence for the protein or polypeptide to be incorporated. One skilled in the art will readily recognize that as more proteins and polypeptides become identified they can be
15 integrated into the vector system of the present invention and expressed in animal or human tissue.

Transfection can be done either by *in vivo* or *ex vivo* techniques. For example, muscle cells can be propagated in culture, transfected with the transforming
20 gene, and then transplanted into muscle tissue. Alternatively, the vectors can be administered to the cells by the methods discussed above.

Methods of Use

A. Treatment with Growth Hormone

25 Growth hormone is normally produced and secreted from the anterior pituitary and promotes linear growth in prepuberty children. Growth hormone acts on the liver and other tissues to stimulate the production of insulin-like growth factor I. This factor is, in turn,
30 responsible for the growth promoting effects of growth hormone. Further, this factor serves as an indicator of overall growth hormone secretion. Serum IGF-I

is secreted from the liver in response to endogenous and

exogenous growth hormone stimulation.

Insulin-like growth factors are one of the key factors that potentiate muscle development and muscle growth. Myoblasts naturally secrete IGF-I/IGF-II as well as its cognate binding proteins during the onset of fusion. This process coincides with the appearance of muscle specific gene products. In terminally differentiated muscle, signals propagated from passive stretch induced hypertrophy induce the expression of IGF genes. Many of the actions of IGFs on muscle result from interactions with the IGF-I receptor.

The intramuscular injection of an expression vector containing the sequence for IGF-I (for example, pIG0552) can be used to treat growth disorders. Vectors are designed to control the expression of IGF-I in a range of 100-400 ng/ml. Since intramuscular expression of vectors leads to expression of the product encoded by the nucleic acid cassette for several months, this method provides a long-term inexpensive way to increase systemic blood concentration of IGF-I in patients with growth hormone deficiency.

B. Effect of IGF-I Vector Expression on Disuse Atrophy

Hindlimb suspension is a common experimental procedure used to induce atrophy of the calf muscles. The effects of hindlimb suspension are similar to those induced by cast immobilization and prolonged exposure to zero gravity.

Mice (12/group) were injected into the gastrocnemius and tibialis anterior muscles with either IGF-I containing vector (IGF-I) or control plasmid (PLAS) at days 0 and 7 of the suspension phase. The vectors were formulated at 3 mg/ml in poly-vinyl

corresponds to a dosage of approximately 1 μ g DNA/mg wet muscle weight.

Contractile force (strength) measurements and muscle weights were taken 1-2 days after cessation of hindlimb suspension. Animal not subjected to hindlimb suspension (NORM) were included for comparison.

Results, shown in Table VI, indicate that hindlimb suspension elicited an approximately 20-25% loss of muscle mass and strength and that treatment with IGF-I vector formulation reduced these effects ($p < .10$).

Table VI
Mean Values for Selected Parameters

Treatment	BW(g)	Tibialis weight (mg)	Tibialis (% body weight)	Tw tension (g)	Tet tension (g)	Gastroc. weight (mg)	Gastroc. (% body weight)
PLAS	27.33	47.39	.174	21.55	69.14	123.69	.454
IGF-I	27.09	50.79	.187	24.00	77.88	128.96	.476
NORM	31.14	59.72	.193	22.19	81.00	163.01	.525

C. Effects of IGF-I Vector Expression Following Crush Denervation

Sciatic nerve crush is a commonly used and well characterized model for elucidating the processes involved in degeneration and regeneration of neuromuscular function following trauma (M. Jaweed, 1994, The Physiological Basis of Rehabilitation, Downey et al., eds., p.543-561. Crush injury to the sciatic nerve results in rapid degeneration of axons distal to the lesion, loss of nerve conduction, and atrophy in the denervated muscle(s).

Early events in nerve regeneration begin within

of normal neuromuscular transmission after approximately

6 weeks in rodents. As a result of denervation, approximately 40-50% atrophy of affected myofibers and a concomitant decrease in isometric contractile force are observed after 14 days with eventual recovery to 80-90% of normal. Recoupment of muscular mass to pre-injury states requires several months.

Previous studies in rodents have indicated that daily administration of rhIGF-I protein can enhance recovery of neuromuscular function following sciatic nerve crush.

Mature ICR strain mice were subjected to either unilateral sham (SHAM) operation or sciatic nerve crush. IGF-I containing vector formulation (IGF-I) or control plasmid (PLAS) was injected into the tibialis anterior and gastrocnemius muscles of the operated limb. Mice in the respective groups were subsequently injected with either IGF-I formulation or control plasmid formulation every 7 days thereafter.

The vectors were formulated at 3 mg/ml in polyvinyl pyrrolidone (PVP) solution and administered at doses of 25 μ l (75 μ g DNA) into the tibialis anterior muscle and 50 μ l (150 μ g DNA) into the gastrocnemius muscle. This corresponds to a dosage of approximately 1 μ g DNA/mg wet muscle weight.

Analyses for contractile force, muscle weight, electromyographic (EMG) activity, and nerve conduction velocity (NCV) were conducted at 14 day intervals following nerve crush. Measurement of EMG activity and NCV were performed using a Dantec Neuromatic 2000 EMG/EP system.

Sciatic nerve crush elicited marked muscle atrophy along with loss of nerve conduction and EMG activity (Figures 10A & B). No significant differences in these

parameters were observed between IGF-I plasmid treated and

control (PLAS) treated mice at any time point.

Improvement in gastrocnemius mass at three weeks post-

crush along with striking improvements in EMG activity and NCV beginning three weeks post-crush. These data suggest that the beneficial effects of hIGF-I plasmid are manifested relatively early (i.e., prior to three weeks) in the regenerative process.

These results indicate that expression from the IGF-I containing vector formulation enhances recovery from sciatic nerve crush.

D. Treatment of Muscle Atrophy Due To Age

Growth hormone levels decline with increasing age. The levels in healthy men and women above age of 55 are approximately one third lower than the levels in men and women 18 to 33. This is associated with a decrease in the concentration of IGF-I. The decline in growth hormone and IGF-I production correlate with the decrease in muscle mass, termed senile muscle atrophy, and increase in adiposity that occur in healthy human subjects. Administering growth hormone three times a week to healthy 61 to 81 year old men who had serum levels below those of healthy younger men increased the serum IGF-I levels to within the range found in young healthy adults. This increased level led to increased muscle mass and strength and reduced body fat. The secretion of growth hormone is regulated by a stimulatory (growth hormone releasing hormone) and an inhibitory (somatostatin) hypothalamic hormone.

The convenient cloning sites in the expression vectors of the present invention are used to construct vectors containing human growth hormone CDNA sequence, the human growth hormone releasing hormone (GHRH), or IGF-I. This versatility is important since the GHRH, GH, and IGF-I, while having equivalent desired effects

It is believed that the expression of either IGF-I

or the growth hormone vectors transcripts. Since GHRH is reduced in the elderly it appears to be responsible for the lack of GH secretion rather than the anterior pituitary capability of synthesizing growth hormone, thus the increased expression of GHRH from muscle would increase GHRH levels in the systemic blood system and can allow for the natural diurnal secretion pattern of GH from the anterior pituitary. In this way, GHRH could act as the natural secretagogue, allowing for elevated secretion or release of GH from the hypothalamus of the elderly.

Thus, the application of vector systems described herein to express insulin-like growth factors through the injection of the pIG0552 or related vectors, the SK 733 IGF-I Sk2 vector, vectors expressing HG, or GHRH into adult muscle of the elderly is a long-term inexpensive way to increase systemic blood concentration of IGF-I in the elderly.

Administration of the vectors can be intravenously, through direct injection into the muscle or by any one of the methods described above. Dosages will depend on the severity of the disease and the amount of dosage is readily determinable by standard methods. The duration of treatment will extend through the course of the disease symptoms which can be continuously.

E. Treatment of Human Muscle Atrophies Induced by Neurological Dysfunction

Insulin-like growth factors are also known neurotrophic agents which maintain neuronal muscular synapses, neuron integrity, and neuronal cell life under neurodegenerative conditions, and positively affect nerve regeneration. Since the expression vector driven genes

can be used to treat the degenerative state of the

remedying the degenerative state of the caused by spinal cord injuries and neuromuscular diseases

caused by drugs, diabetes, Type I disease, Type II diabetes, genetic diseases such as CHACOT-marie-tooth disease or certain other diseases. Moreover, IGF-I secretion can induce neurite outgrowth. In this treatment, the product of the vector acts as a neurotrophic agent secreted from injected muscle and as a hypertrophic agent to maintain muscle integrity.

Administration of the vectors can be intravenously, through direct injection or by any one of the methods described above. Dosages will depend on the severity of the disease and the amount of dosage is readily determinable by standard methods. The duration of treatment will extend through the course of the disease symptoms which can be continuously.

15 F. Treatment of Diabetes

Insulin plays a central role in the regulation of carbohydrate, fat and protein metabolism. With diabetics, treatment with insulin can result in insulin resistance in which insulin treatment will not result in adequate metabolic control. This resistance can occur in the presence of circulating insulin or insulin-receptor antibodies or insulin-receptor abnormalities or episodically in patients with previously typical insulin-dependent diabetes mellitus. Therapeutic options are limited with patients suffering from severe insulin resistance.

IGF-I can be used in the treatment of insulin resistance. Treatment with IGF-I using the vectors of the present invention will achieve glycemic control by reversing hyperglycemia and ketoacidosis. Treatment with IGF-I will also improve the degree of insulin sensitivity. The convenient cloning sites in the expression vectors of the present invention are used to construct vectors containing

5

G. Treatment of Peripheral Neuropathies

10

20

30

H. Treatment of Osteoporosis

Osteoporosis is a common accelerated loss of bone mass that often accompanies aging. The decreased bone density associated with osteoporosis leads to an increased susceptibility to bone fractures. Treatment with IGF-I is associated with increased bone density. Administration of a vector encoding IGF-I to muscles by direct injection or hypospray will aid in the redeposition of bone and thereby decrease the risk of fractures.

Administration of the vectors can be intravenously, through direct injection or by any one of the methods described above. Dosages will depend on the severity of the disease and the amount of dosage is readily determinable by standard methods. The duration of treatment will extend through the course of the disease symptoms which can be continuously.

Transgenic Swine

An additional embodiment of the present invention is the 5 generation of improved domestic livestock. Specifically, introduction of the vector pIG0552, or a vector expressing IGF-I of porcine, bovine or ovine derivation into oocytes of domestic swine by the method described above for the generation of transgenic mice will generate swine expressing IGF-I in myogenic tissue. These transgenic swine have the desired livestock characteristics of increased muscle mass and reduced fat.

In addition, by providing contiguous 3' NCR, IGF-I is buffered against outside genomic sequences and is thus more protected from position effects, when integrated into the genome. In addition, by providing natural terminating sequences, the additional regulatory sequences that mark the transcriptional domain of skeletal α -actin prevent

integrated vector to produce 40-50% of the transcriptional activity of the endogenous sequences.

Improvement of Livestock

An additional embodiment of the present invention is the improvement of livestock by injection of IGF-I vector constructs, or similar constructs encoding other growth hormones, such as growth hormone or growth hormone releasing hormone. Muscle injection of vectors encoding IGF-I by hypodermic or hypospray administration will promote increased muscle mass and reduced body fat in important livestock species such as cattle, sheep, swine, rabbits, deer, fish and birds such as turkeys, chickens, ducks, and geese. Administration of the vectors can also be through any one of the methods described above.

One skilled in the art will readily appreciate that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned as well as those inherent therein. The vector systems along with the methods, procedures treatments and vaccinations described herein are presently representative of preferred embodiments are exemplary and not intended as limitations on the scope of the invention. Changes therein and other uses will occur to those skilled in the art which are encompassed within the spirit of the invention or defined by this scope with the claims.

It will be readily apparent to one skilled in the art that varying substitutions and modifications may be made to the invention disclosed herein within departing from the scope and spirit of the invention.

All patents and publications mentioned in the specification are indicative of the levels of those skilled in the art to which the invention pertains. All

publications mentioned herein are hereby incorporated by reference.

Claims

1. A vector for expression of a nucleic acid sequence in a cell, comprising:
 - a nucleic acid cassette containing a nucleotide
5 sequence encoding IGF-I; - a 5' flanking region including one or more sequences necessary for expression of said nucleic acid cassette, wherein said sequences include a promoter from a skeletal α -actin gene; - 10 a linker connecting said 5' flanking region to a nucleic acid, said linker having a position for inserting said nucleic acid cassette, wherein said linker lacks the coding sequence of a gene with which it is naturally associated; and
15 a 3' flanking region, including a 3'UTR or a 3'NCR or both, wherein said 3' flanking region is 3' to said position for inserting said nucleic acid cassette, and wherein said 3' flanking region comprises a sequence from a growth hormone 3'-UTR.
- 20 2. The vector of claim 1, wherein said IGF-I is human IGF-I.
3. The vector of claim 2, wherein said nucleotide sequence encoding for human IGF-I is a synthetic sequence.
4. The vector of claim 3, wherein said nucleotide
25 sequence encoding for human IGF-I has the sequence of SEQ ID NO. 4.
5. The vector of claim 1, wherein said promoter from a skeletal α -actin gene is from a chicken.

7. The vector of claim 1, wherein said growth hormone 3'-UTR is from a human growth hormone gene.

8. The vector of claim 1, wherein an ALU repeat or ALU repeat-like sequence is deleted from said 3' UTR.

5 9. The vector of claim 1, wherein said IGF-I is human IGF-I, said promoter from a skeletal α -actin gene is from a chicken, and said growth hormone 3'-UTR is from a human growth hormone gene.

10 10. The vector of claim 1, wherein said 5' flanking region or said 3' flanking region or both regulates expression of said nucleic acid cassette predominately in a specific tissue.

11. The vector of claim 2, wherein said specific tissue is myogenic.

15 12. The vector of claim 1, wherein said 5' flanking region includes a promoter, a TATA box, a Cap site and a first intron and intron/exon boundary in appropriate relationship for expression of said nucleic acid cassette.

20 13. The vector of claim 12, wherein said 5' flanking region further comprises a 5' mRNA leader sequence inserted between said promoter and said nucleic acid cassette.

25 14. The vector of claim 1, wherein said vector further comprises an intron/5' UTR from a chicken skeletal α -actin gene.

15. The vector of claim 1, wherein said vector

16. The vector of claim 1, wherein said vector comprises a nucleotide sequence which is the same as the nucleotide sequence of plasmid pIG0552.

17. A formulation for delivery and expression of a
5 human IGF-I gene in a cell, said formulation comprising
a vector of claim 1 in a solution having between 0.5%
and 50% PVP.

18. The formulation of claim 17, wherein said solution includes about 5% PVP.

10 19. A transgenic animal having a plurality of cells containing the vector of claim 1.

20. The transgenic animal of claim 19, wherein said cell is a germ or somatic cell.

21. A cell transformed with a vector of claim 1.

15 22. The transformed cell of claim 21, wherein said cell is myogenic.

23. A method for transfection of a cell *in situ*, comprising the step of contacting said cell with a vector of claim 1 for sufficient time to transfect said cell.

20 24. The method of claim 23, wherein transfection of said cell is performed *in vivo*.

25. The method of claim 24, wherein said contacting is performed in the presence of an about 5% PVP solution.

26. The method of claim 25, wherein said contacting is performed in the presence of a selectable marker and selecting the transformed cells.

27. A method for delivery and expression of a human IGF-I gene in a plurality of cells, comprising the steps of:

(a) transfecting said plurality of cells with
5 a vector of claim 1; and

(b) incubating said plurality of cells under conditions allowing expression of a nucleic acid sequence in said vector, wherein said nucleic acid sequence encodes IGF-I.

10 28. The method of claim 27, wherein said IGF-I is hIGF-I and said cells are human cells.

29. The method of claim 28, wherein said contacting is performed in the presence of an about 5% PVP solution.

15 30. A method for treating a disease or condition, comprising the steps of transfecting a cell *in situ* with a vector of claim 1.

31. The method of claim 30, wherein said disease or condition is a localized disease or condition.

20 32. The method of claim 30, wherein said disease or condition is a systemic disease or condition.

33. The method of claim 30, wherein said disease or condition to be treated is selected from the group consisting of muscle atrophy, osteoporosis, diabetes, neuropathy and growth disorders.

25 34. The method of claim 30, wherein said disease or condition is muscle atrophy secondary to lower motor

Restriction Map of the Chicken Skeletal alpha Actin Gene




FIGURE 1

Myogenic Vector System




FIGURE 2

3/16

Skeletal Actin / Insulin Like Growth Factor Hybrid Genes






FIGURE 3

4/16




SUBSTITUTE SHEET (RULE 26)

5/16

**Fig. 5**

6/16

**Fig. 6**





Fig. 7

8/16



SUBSTITUTE SHEET (RULE 26)

Fig. 9


Codon Frequency Tables

human_high.cod


Codon usage for human (highly expressed) genes 1/10/91

Amino Acid	Codon	Number	/1000	Fraction	..
Ala	GCG	981.00	18.76	0.26	
Ala	GCA	523.00	10.06	0.14	
Ala	GCT	441.00	9.14	0.12	
Ala	GCC	1047.00	18.70	0.16	
Asp	GAA	6470.00	30.16	0.75	
Asp	GAA	782.00	16.42	0.25	
Asp	GAT	592.00	12.27	0.25	
Asp	GAC	1021.00	17.73	0.75	
Asn	GTG	1864.00	30.68	0.66	
Asn	GTA	134.00	2.78	0.05	
Asn	GTT	190.00	4.10	0.07	
Asn	GTG	728.00	15.69	0.25	
Asp	GCG	651.00	13.51	0.17	
Asp	GCA	486.00	10.12	0.13	
Asp	GCT	636.00	13.56	0.17	
Asp	GCC	1057.00	12.64	0.13	
Asp	AGC	512.00	10.61	0.18	
Asp	AGA	294.00	6.18	0.10	
Asp	AGT	354.00	7.14	0.13	
Asp	AGC	1171.00	24.27	0.36	
Lys	AAC	2117.00	43.18	0.82	
Lys	AAG	671.00	9.76	0.16	
Lys	AAT	316.00	6.51	0.12	
Lys	AAC	1120.00	23.12	0.36	
Met	ATG	1077.00	22.12	1.00	
Phe	ATT	48.00	1.02	0.05	
Phe	ATT	115.00	2.53	0.10	
Phe	ATC	1368.00	28.18	0.77	
Thr	ACT	405.00	8.10	0.15	
Thr	ACA	371.00	7.73	0.16	
Thr	ACT	356.00	7.42	0.16	
Thr	ACC	1502.00	32.13	0.37	
Trp	TGG	632.00	13.51	1.00	
Val	TGA	109.00	2.26	0.15	
Val	TGT	323.00	6.74	0.22	
Val	TGC	704.00	14.63	0.68	
Val	TAC	42.00	0.87	0.11	
Val	TAA	46.00	0.95	0.23	
Tyr	TAT	368.00	7.46	0.16	
Tyr	TAC	1042.00	21.60	0.76	
Leu	TTG	313.00	6.49	0.46	
Leu	TTA	76.00	1.56	0.02	
Phe	TTT	316.00	6.56	0.10	
Phe	TTG	1377.00	28.54	0.10	
Leu	TGG	329.00	6.74	0.19	
Leu	TGA	168.00	3.42	0.05	
Leu	TGT	436.00	9.33	0.13	
Leu	TGC	950.00	19.66	0.26	
Arg	CGG	311.00	12.67	0.21	
Arg	CGA	183.00	3.79	0.06	
Arg	CGT	218.00	4.23	0.07	
Arg	CGC	1006.00	22.52	0.19	
Gln	CAG	2620.00	41.87	0.10	
Gln	CAG	283.00	5.87	0.12	
Gln	CAT	234.00	4.86	0.07	
Gln	CAC	870.00	18.03	0.79	
Leu	CTC	1004.00	19.70	0.14	
Leu	CTA	166.00	3.42	0.05	
Leu	CTG	34.00	0.72	0.01	
Leu	CTC	136.00	2.93	0.10	
Leu	CTT	168.00	3.77	0.11	
Leu	CTC	1410.00	29.23	0.11	

10/16

**Fig. 10A**

11/16

**Fig. 10B**

12/16

Optimization of IGF-I sequence

Step 1:

Nucleotide sequence of IGF-I CDS of pIG0552 (2885-3346) SEQ. ID. NO. 1

```
2851                               ATGGGA AAAATCAGCA
2901  GTCTTCCAAC CCAATTATTT AAGTGCTGCT TTTGTGATTT CTTGAAGGTG
2951  AAGATGCACA CCATGTCCTC CTCGCATCTC TTCTACCTGG CGCTGTGCCT
3001  GCTCACCTTC ACCAGCTCTG CCACGGCTGG ACCGGAGACG CTCTGCGGGG
3051  CTGAGCTGGT GGATGCTCTT CAGTTCGTGT GTGGAGACAG GGGCTTTTAT
3101  TTCAACAAGC CCACAGGGTA TGGCTCCAGC AGTCGGAGGG CGCCTCAGAC
3151  AGGCATCGTG GATGAGTGCT GCTTCCGGAG CTGTGATCTA AGGAGGCTGG
3201  AGATGTATTG CGCACCCCTC AAGCCTGCCA AGTCAGCTCG CTCTGTCCGT
3251  GCCCAGCGCC ACACCGACAT GCCCAAGACC CAGAAGGAAG TACATTTGAA
3301  GAACGCAAGT AGAGGGAGTG CAGGAAACAA GAACTACAGG ATGTAG
```

FIGURE 11

Step 3: Optimized IGF-I sequence: Contains optimized human codons

SEQ. ID. NO. 4

```
1  ATGGGCAAGA TCAGCAGCCT GCCCACCAG CTGTTCAAGT GCTGCTTCTG
51  CGACTTCCTG AAGGTGAAGA TGCACACCAT GAGCAGCAGC CACCTGTTCT
101 ACCTGGCCCT GTGCCTGCTG ACCTTCACCA GCAGCGCCAC CGCCGGCCCC
151 GAGACCCTGT GCGGCGCCGA GCTGGTGGAC GCCCTGCAGT TCGTGTGCGG
201 CGACCGCGGC TTCTACTTCA ACAAGCCCAC CGGCTACGGC AGCAGCAGCC
251 GCCGCGCCCC CCAGACCGGC ATCGTGGACG AGTGCTGCTT CCGCAGCTGC
301 GACCTGCGCC GCCTGGAGAT GTACTGCGCC CCCCTGAAGC CCGCCAAGAG
351 CGCCCGCAGC GTGCGCGCCC AGCGCCACAC CGACATGCCC AAGACCCAGA
401 AGGAGGTGCA CCTGAAGAAC GCCAGCCGCG GCAGCGCCGG CAACAAGAAC
451 TACCGCATGT GA
```

FIGURE 12

Step 2: Translation of CDS of pIG0552 SEQ. ID. NO. 5

1 MGKISSSLPTQ LFKCCFCDFL KVKMHTMSSS HLFYLALCLL TFTSSATAGP
51 ETLCGAELVD ALQFVCGDRG FYFNKPTGYG SSSRRAPQTG IVDECCFRSC
101 DLRRLEMYCA PLKPAKSARS VRAQRHTDMP KTQKEVHLKN ASRGSAGNKN
151 YRM*

FIGURE 13

Step 5: Homology between WT and optimized IGF-I sequence

Gap Weight: 5.000 Average Match: 1.000
Length Weight: 0.300 Average Mismatch: -0.900

Quality: 285.2 Length: 460
Ratio: 0.620 Gaps: 0
Percent Similarity: 80.000 Percent Identity: 80.000

Top: WT SEQ. ID. NO. 1
Bottom: Optimized for human codons SEQ. ID. NO. 4

```
2885 ATGGGAAAAATCAGCAGTCTTCCAACCCAATTATTTAAGTGCTGCTTTTG 2934
      ||||| || ||||| || || ||||| || || ||||| ||||| ||
      1 ATGGGCAAGATCAGCAGCCTGCCCCACCCAGCTGTTCAAGTGCTGCTTCTG 50
2935 TGATTTCTTGAAGGTGAAGATGCACACCATGTCCTCCTCGCATCTCTTCT 2984
      || ||||| ||||| ||||| ||||| || || || || |||||
      51 CGACTTCCTGAAGGTGAAGATGCACACCATGAGCAGCAGCCACCTGTTCT 100
2985 ACCTGGCGCTGTGCCTGCTCACCTTCACCAGCTCTGCCACGGCTGGACCG 3034
      ||||| ||||| ||||| ||||| ||||| || || || ||
      101 ACCTGGCCCTGTGCCTGCTGACCTTCACCAGCAGCGCCACCGCCGGCCCC 150
3035 GAGACGCTCTGCGGGGCTGAGCTGGTGGATGCTCTCAGTTCGTGTGTGG 3084
      ||||| || ||||| || ||||| || || ||||| ||||| ||
      151 GAGACCCCTGTGCGGCGCCGAGCTGGTGGACGCCCTGCAGTTCGTGTGCGG 200
3085 AGACAGGGGGCTTTTATTTCAACAAGCCCACAGGGTATGGCTCCAGCAGTC 3134
      ||| | ||||| || ||||| ||||| || || || ||||| |
      201 CGACCGCGGCTTCTACTTCAACAAGCCCACCGGCTACGGCAGCAGCAGCC 250
3135 GGAGGGCGCCTCAGACAGGCATCGTGGATGAGTGCTGCTTCCGGAGCTGT 3184
      | | || || ||||| ||||| ||||| ||||| |||||
      251 GCCGCGCCCCCAGACCGGCATCGTGGACGAGTGCTGCTTCCGCAGCTGC 300
3185 GATCTAAGGAGGCTGGAGATGTATTGCGCACCCTCAAGCCTGCCAAGTC 3234
      || || | ||||| ||||| ||||| ||||| ||||| |||||
      301 GACCTGCGCCGCTGGAGATGTACTGCGCCCCCTGAAGCCCGCCAAGAG 350
3235 AGCTCGCTCTGTCCGTGCCCAGCGCCACACCGACATGCCCAAGACCCAGA 3284
      || ||| || || ||||| ||||| ||||| ||||| |||||
      351 CGCCCGCAGCGTGCGCGCCCAGCGCCACACCGACATGCCCAAGACCCAGA 400
3285 AGGAAGTACATTTGAAGAACGCAAGTAGAGGGAGTGCAGGAAACAAGAAC 3334
      |||| || || ||||| ||||| || || || || |||||
      401 AGGAGGTGCACCTGAAGAACGCCAGCCGCGGCAGCGCCGCAACAAGAAC 450
3335 TACAGGATGT 3344
      || || ||||
```

16/16




FIGURE 15

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 97/21852

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/85 C07K14/65 A61K48/00 A01K67/027

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K A61K A01K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 93 09236 A (BAYLOR COLLEGE MEDICINE) 13 May 1993 cited in the application see examples 1,2	1-34
Y	COLEMAN M E ET AL: "Myogenic Vector Expression of Insulin -like Growth Factor I Stimulates Muscle Cell Differentiation and Myofiber Hypertrophy in Transgenic Mice." JOURNAL OF BIOLOGICAL CHEMISTRY 270 (20). 1995. 12109-12116. ISSN: 0021-9258, XP000611917 see the whole document	1-34



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "Z" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentanwälte
NL - 2280 HV Rijswijk
Tel (+31-70) 340-2040, Tx 31 651 epo nl
Fax: (+31-70) 340-3016

Authorized officer

Hix, R

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 97/21852

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,Y	<p>DRAGHIA-AKLI R ET AL: "Enhanced growth by ectopic expression of growth hormone releasing hormone using an injectable myogenic vector."</p> <p>NATURE BIOTECHNOLOGY 15 (12). 1997. 1285-1289. ISSN: 1087-0156, XP002060954</p> <p>see the whole document</p> <p>---</p>	1-34
P,Y	<p>WANG J ET AL: "Targeted overexpression of IGF-I evokes distinct patterns of organ remodeling in smooth muscle cell tissue beds of transgenic mice."</p> <p>JOURNAL OF CLINICAL INVESTIGATION 100 (6). 1997. 1425-1439. ISSN: 0021-9738, XP002060955</p> <p>see the whole document</p> <p>-----</p>	1-34

INTERNATIONAL SEARCH REPORT

In international application No.
PCT/US 97/21852

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

☐ No protest accompanied the payment of additional search fees

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 97/21852

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Remark : Although claims 23-25 and 30-34 are directed to a method of treatment of the human/animal body , the search has been carried out and based on the alleged effects of the compound/composition.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/21852

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9309236 A	13-05-93	US 5298422 A	29-03-94
		AU 660751 B	06-07-95
		AU 3124693 A	07-06-93
		CA 2122617 A	13-05-93
		EP 0635060 A	25-01-95
		JP 7500967 T	02-02-95
		PT 101042 A	28-02-94
